Dactolisib (BEZ235, NVP-BEZ235)

Catalog No.S1009

Molecular Weight(MW): 469.55

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell.

Cited by 258 Publications

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2018, 560(7718):372-376

PubMed: 30046109 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Cancer Cell, 2017, 31(3):424-435

PubMed: 28292440 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Nature, 2014, 514(7524):628-32

PubMed: 25119024 ( click the link to review the publication )

Nature, 2012, 487(7408):505-9

PubMed: 22763448 ( click the link to review the publication )

Cancer Cell, 2012, 21(2):155-67

PubMed: 22340590 ( click the link to review the publication )

Gastroenterology, 2019, 10.1053/j.gastro.2019.11.013

PubMed: 31734182 ( click the link to review the publication )

Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Cell Rep, 2019, 27(3):820-834

PubMed: 30995479 ( click the link to review the publication )

Cell Rep, 2019, 26(3):608-623

PubMed: 30650355 ( click the link to review the publication )

Cell Death Differ, 2019, 26(9):1670-1687

PubMed: 30683918 ( click the link to review the publication )

Radiology, 2019, 10.1148/radiol.2019190115

PubMed: 31335281 ( click the link to review the publication )

Oncogene, 2019, 38(15):2690-2705

PubMed: 30538293 ( click the link to review the publication )

J Pathol, 2019, 10.1002/path.5277

PubMed: 30957234 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):282

PubMed: 31262325 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):481

PubMed: 31801598 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(13):4063-4078

PubMed: 30952635 ( click the link to review the publication )

Cancers, 2019, 11(2)

PubMed: 30813295 ( click the link to review the publication )

Cancers, 2019, 11(5)

PubMed: 31121848 ( click the link to review the publication )
Mol Ther Nucleic Acids, 2019, 14:287-300

PubMed: 30654190 ( click the link to review the publication )

Biomacromolecules, 2019, 20(9):3313-3323

PubMed: 31198025 ( click the link to review the publication )

J Dent Res, 2019, 98(3):304-312

PubMed: 30513244 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163

PubMed: 31289138 ( click the link to review the publication )

Front Oncol, 2019, 9:463

PubMed: 31214505 ( click the link to review the publication )

Front Oncol, 2019, 9:463

PubMed: 31214505 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113640

PubMed: 31536726 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5309

PubMed: 30926929 ( click the link to review the publication )

J Cancer, 2019, 10(5):1197-1208

PubMed: 30854129 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(1):145-159

PubMed: 30755818 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:336

PubMed: 31871431 ( click the link to review the publication )

J Cell Physiol, 2019, 234(10):18249-18261

PubMed: 30851074 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:7933-7951

PubMed: 31686909 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(7):2764-2772

PubMed: 31247083 ( click the link to review the publication )

Transl Oncol, 2019, 12(3):404-416

PubMed: 30550927 ( click the link to review the publication )

Am J Transl Res, 2019, 11(1):87-105

PubMed: 30787971 ( click the link to review the publication )

Int J Mol Med, 2019, 43(1):47-56

PubMed: 30387804 ( click the link to review the publication )

Vet Comp Oncol, 2019, 10.1111/vco.12490

PubMed: 31069942 ( click the link to review the publication )

Pharm Biol, 2019, 57(1):412-423

PubMed: 31230505 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3745-3755

PubMed: 31262901 ( click the link to review the publication )

Ren Fail, 2019, 41(1):267-277

PubMed: 30982374 ( click the link to review the publication )

Assay Drug Dev Technol, 2019, 17(3):140-149

PubMed: 30958703 ( click the link to review the publication )

Nagoya J Med Sci, 2019, 81(1):93-102

PubMed: 30962658 ( click the link to review the publication )
Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Viruses, 2019, 11(3)

PubMed: 30875748 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Cancer Res, 2018, 78(9):2383-2395

PubMed: 29440171 ( click the link to review the publication )

Cancer Res, 2018, 78(13):3645-3658

PubMed: 29760043 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4396-4410

PubMed: 29844118 ( click the link to review the publication )

Radiology, 2018, 288(3):730-738

PubMed: 29737948 ( click the link to review the publication )

J Invest Dermatol, 2018, 138(11):2377-2387

PubMed: 29758280 ( click the link to review the publication )

J Pathol, 2018, 245(1):101-113

PubMed: 29443392 ( click the link to review the publication )

Cancers, 2018, 10(2)

PubMed: 29370086 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):123

PubMed: 29374144 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):45

PubMed: 29352118 ( click the link to review the publication )

J Cancer, 2018, 9(6):987-997

PubMed: 29581778 ( click the link to review the publication )

Glia, 2018, 66(5):999-1015

PubMed: 29392777 ( click the link to review the publication )

Exp Mol Med, 2018, 50(3):e463

PubMed: 29869624 ( click the link to review the publication )

Radiat Oncol, 2018, 13(1):76

PubMed: 29685176 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(2):347-354

PubMed: 28958992 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(4):599-609

PubMed: 29330285 ( click the link to review the publication )

Front Oncol, 2018, 8:249

PubMed: 30013951 ( click the link to review the publication )

Front Oncol, 2018, 8:249

PubMed: 30013951 ( click the link to review the publication )

Antiviral Res, 2018, 153:39-48

PubMed: 29425831 ( click the link to review the publication )

Biochem Pharmacol, 2018, 10.1016/j.bcp.2018.10.011

PubMed: 30342021 ( click the link to review the publication )
Biochem Pharmacol, 2018, 10.1016/j.bcp.2018.10.011

PubMed: 30342021 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Acta Pharmacol Sin, 2018, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Invest New Drugs, 2018, 10.1007/s10637-018-0698-2

PubMed: 30456603 ( click the link to review the publication )

Int J Hyperthermia, 2018, 34(6):812-823

PubMed: 28954551 ( click the link to review the publication )

Cancer Med, 2018, 7(9):4744-4754

PubMed: 30109783 ( click the link to review the publication )

Am J Transl Res, 2018, 10(12):4376-4384

PubMed: 30662679 ( click the link to review the publication )

Oncol Rep, 2018, 39(2):711-720

PubMed: 29207150 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2353-2362

PubMed: 30066933 ( click the link to review the publication )

Oncol Rep, 2018, 39(4):1731-1738

PubMed: 29393465 ( click the link to review the publication )

J Cell Biochem, 2018, 119(3):2708-2718

PubMed: 29057547 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):2461-2472

PubMed: 29436587 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):2755-2763

PubMed: 29436606 ( click the link to review the publication )

PLoS One, 2018, 13(1):e0190854

PubMed: 29357370 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 507(1-4):311-318

PubMed: 30466782 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 495(2):2004-2009

PubMed: 29253572 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 504(4):721-726

PubMed: 30217442 ( click the link to review the publication )

Anticancer Res, 2018, 38(3):1407-1414

PubMed: 29491065 ( click the link to review the publication )

Pathol Res Pract, 2018, 214(6):889-895

PubMed: 29653746 ( click the link to review the publication )

Oncol Lett, 2018, 15(6):9655-9662

PubMed: 29928341 ( click the link to review the publication )

Oncotarget, 2018, 9(6):7023-7035

PubMed: 29467947 ( click the link to review the publication )

Sci Rep, 2018, 8(1):1652

PubMed: 29374181 ( click the link to review the publication )

Discov Med, 2018, 25(140):265-275

PubMed: 30021100 ( click the link to review the publication )

Mol Cell, 2017, 65(6):999-1013

PubMed: 28306514 ( click the link to review the publication )
Nano Lett, 2017, 17(11):7160-7168

PubMed: 29035540 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1636

PubMed: 29158506 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1278

PubMed: 29097657 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(5):1274-1285

PubMed: 28232476 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3045-3052

PubMed: 28007777 ( click the link to review the publication )

Leukemia, 2017, 31(4):922-933

PubMed: 27686868 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(7):E1072-E1080

PubMed: 28137841 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(5):1286-1298

PubMed: 27553832 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):9

PubMed: 28061880 ( click the link to review the publication )

Cancer Lett, 2017, 388:12-20

PubMed: 27894954 ( click the link to review the publication )

Cancer Lett, 2017, 406:1-11

PubMed: 28774796 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(5):1813-1828

PubMed: 29065414 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(4):729-738

PubMed: 28119490 ( click the link to review the publication )

J Nutr Biochem, 2017, 41:124-136

PubMed: 28092744 ( click the link to review the publication )

J Cell Mol Med, 2017, 21(3):467-474

PubMed: 27680680 ( click the link to review the publication )

Mol Imaging Biol, 2017, 19(3):421-428

PubMed: 27770401 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(3):382-391

PubMed: 28042875 ( click the link to review the publication )

Mol Cell Neurosci, 2017, 82:66-75

PubMed: 28461220 ( click the link to review the publication )

World J Gastroenterol, 2017, 23(42):7551-7562

PubMed: 29204055 ( click the link to review the publication )

Drug Des Devel Ther, 2017, 11:1115-1126

PubMed: 28435223 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:5077-5087

PubMed: 29118584 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 491(1):209-216

PubMed: 28712871 ( click the link to review the publication )

Oncol Lett, 2017, 14(6):7970-7976

PubMed: 29250185 ( click the link to review the publication )

Oncotarget, 2017, 8(33):53968-53977

PubMed: 28903316 ( click the link to review the publication )
Oncotarget, 2017, 8(64):107977-107990

PubMed: 29296217 ( click the link to review the publication )

Oncotarget, 2017, 8(7):11937-11949

PubMed: 28060760 ( click the link to review the publication )

Nat Commun, 2016, 7:11971

PubMed: 27321283 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

EMBO J, 2016, 35(20):2192-2212

PubMed: 27625374 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(11):2744-54

PubMed: 26712685 ( click the link to review the publication )

J Exp Clin Cancer Res, 2016, 35:52

PubMed: 27009084 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2016, 29(6):643-655

PubMed: 27463366 ( click the link to review the publication )

Mol Oncol, 2016, 10(1):101-12

PubMed: 26471831 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Mol Carcinog, 2016, 55(12):2135-2155

PubMed: 26764221 ( click the link to review the publication )

Int J Oncol, 2016, 49(1):285-93

PubMed: 27176231 ( click the link to review the publication )

Biomed Pharmacother, 2016, 77:161-6

PubMed: 26796280 ( click the link to review the publication )

BMC Cancer, 2016, 16:657

PubMed: 27542970 ( click the link to review the publication )

Int J Biochem Cell Biol, 2016, 79:393-400

PubMed: 27620077 ( click the link to review the publication )

Cancer Med, 2016, 5(10):2953-2964

PubMed: 27539383 ( click the link to review the publication )

Transl Oncol, 2016, 9(3):197-202

PubMed: 27267837 ( click the link to review the publication )

Animal, 2016, 10(8):1319-27

PubMed: 26956906 ( click the link to review the publication )

Anticancer Res, 2016, 36(4):1673-82

PubMed: 27069145 ( click the link to review the publication )

Target Oncol, 2016, 11(2):209-27

PubMed: 26453055 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )

Tumour Biol, 2016, 37(1):419-24

PubMed: 26219899 ( click the link to review the publication )

Heliyon, 2016, 2(11):e00194

PubMed: 27896318 ( click the link to review the publication )
Oncotarget, 2016, 8(32):52193-52210

PubMed: 28881723 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3947-65

PubMed: 26678033 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13797-809

PubMed: 26883194 ( click the link to review the publication )

J Clin Invest, 2015, 125(3):1174-88

PubMed: 25664849 ( click the link to review the publication )

Nano Lett, 2015, 15(12):8032-43

PubMed: 26540670 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(24):5499-5510

PubMed: 26272063 ( click the link to review the publication )

Leukemia, 2015, 29(4):828-38

PubMed: 25322685 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2014.444

PubMed: 25619831 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.143

PubMed: 25961924 ( click the link to review the publication )

EBioMedicine, 2015, 2(12):1944-56

PubMed: 26844273 ( click the link to review the publication )

Cancer Lett, 2015, 367(1):58-68

PubMed: 26188279 ( click the link to review the publication )

Cancer Lett, 2015, 359(1):47-56

PubMed: ( click the link to review the publication )

Breast Cancer Res, 2015, 17:32

PubMed: 25849721 ( click the link to review the publication )

J Neurosci, 2015, 35(9):3893-902

PubMed: 25740518 ( click the link to review the publication )

Cancer Discov, 2015, 5(12):1262-70

PubMed: 26370156 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(4):1014-23

PubMed: 25673820 ( click the link to review the publication )

Neoplasia, 2015, 17(1):16-31

PubMed: 25622896 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(10):2193-8

PubMed: 26270491 ( click the link to review the publication )

J Biol Chem, 2015, 290(28):17495-504

PubMed: 26023239 ( click the link to review the publication )

Cancer Cell Int, 2015, 15:65

PubMed: 26130968 ( click the link to review the publication )

J Dermatol Sci, 2015, 78(1):44-50

PubMed: 25726712 ( click the link to review the publication )

Mol Imaging Biol, 2015, 17(3):403-12

PubMed: 25465391 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(4):580-8

PubMed: 25793663 ( click the link to review the publication )

Prostate, 2015, 75(15):1747-59

PubMed: 26250606 ( click the link to review the publication )
BMC Cancer, 2015, 15:894

PubMed: 26560145 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0144708

PubMed: 26678268 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Onco Targets Ther, 2015, 8:269-77

PubMed: 25674002 ( click the link to review the publication )

Biomed Res Int, 2015, 2015:870918

PubMed: 26557706 ( click the link to review the publication )

Cytometry A, 2015, 10.1002/cyto.a.22628

PubMed: 25598437 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )

EJNMMI Res, 2015, 5(1):61

PubMed: 26543028 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(2):404-12

PubMed: 24192926 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(8):2126-35

PubMed: 24573549 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(5):1235-48

PubMed: 24366691 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2846-56

PubMed: 24614082 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.12.034

PubMed: 25554016 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 10.1111/pcmr.12268

PubMed: 24890688 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1434

PubMed: 25275595 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1013

PubMed: 24457957 ( click the link to review the publication )

FASEB J, 2014, fj.13-247924

PubMed: 24903273 ( click the link to review the publication )

Mol Oncol, 2014, 8(3):544-54

PubMed: 24476679 ( click the link to review the publication )
J Virol, 2014, 88(9):5152-64

PubMed: 24574393 ( click the link to review the publication )

Magnet Reson Med, 2014, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

Apoptosis, 2014, 19(5):895-904

PubMed: 24652480 ( click the link to review the publication )

Endocrinology, 2014, 155(4):1510-9

PubMed: 24476133 ( click the link to review the publication )

Expert Opin Inv Drugs, 2014, 23(4):469-87

PubMed: 24490883 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(13):2517-32

PubMed: 24777602 ( click the link to review the publication )

Invest New Drugs, 2014, 32(6):1134-43

PubMed: 25152245 ( click the link to review the publication )

Anal Bioanal Chem, 2014, 406(15):3743-54

PubMed: 24817345 ( click the link to review the publication )

BMC Cancer, 2014, 14:283

PubMed: 24758408 ( click the link to review the publication )

Eur J Pharmacol, 2014, 741:195-204

PubMed: 25160744 ( click the link to review the publication )

Drug Des Devel Ther, 2014, 8:255-62

PubMed: 24600206 ( click the link to review the publication )

PLoS One, 2014, 9(2):e88587

PubMed: 24523919 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

PLoS One, 2014, 9(8):e105280

PubMed: 25144531 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108193

PubMed: 25247710 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Cardiovasc Inter Rad, 2014, 37(5):1343-51

PubMed: 24452318 ( click the link to review the publication )

Eur Biophys J, 2014, 9(4):e95243

PubMed: 24743578 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Nat Chem Biol, 2013, 9(11):708-14

PubMed: 24013279 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )

Cancer Res, 2013, 73(11):3402-11

PubMed: 23585456 ( click the link to review the publication )
Cell Death Differ, 2013, 21(3):491-502

PubMed: 24362439 ( click the link to review the publication )

Int J Cancer, 2013, 133(2):505-13

PubMed: 23319394 ( click the link to review the publication )

Int J Cancer, 2013, 133(9):2089-101

PubMed: 23629727 ( click the link to review the publication )

Oncogene, 2013, 32(17):2179-88

PubMed: 22689062 ( click the link to review the publication )

Cancer Lett, 2013, 329(2):236-42

PubMed: 23200669 ( click the link to review the publication )

Sci Signal, 2013, 6(271):ra25

PubMed: 23592840 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(1):R16

PubMed: 23448424 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2013, 26(4):518-26

PubMed: 23582185 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e64

PubMed: 24263233 ( click the link to review the publication )

J Mater Chem B, 2013, 5602-5610

PubMed: ( click the link to review the publication )

Cancer Sci, 2013, 104(7):896-903

PubMed: 23578175 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(10):1269-78

PubMed: 23814023 ( click the link to review the publication )

Magn Reson Med, 2013, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )

J Biol Chem, 2013, 288(42):30387-98

PubMed: 24014036 ( click the link to review the publication )

Acta Pharmacol Sin, 2013, 34(5):681-90

PubMed: 23603977 ( click the link to review the publication )

Transl Oncol, 2013, 6(5):586-95

PubMed: 24151539 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1297-307

PubMed: 23479136 ( click the link to review the publication )

PLoS One, 2013, 8(3):e59879

PubMed: 23533654 ( click the link to review the publication )

J Biomol Screen, 2013, 19(1):131-44

PubMed: 23954931 ( click the link to review the publication )

J Thorac Oncol, 2012, 7(2):272-80

PubMed: 22089117 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(9):2515-25

PubMed: 22392911 ( click the link to review the publication )

Eur J Cancer, 2012, 48(6):936-43

PubMed: 22088482 ( click the link to review the publication )

Oncogene, 2012, 33(2):236-45

PubMed: 23246970 ( click the link to review the publication )

J Invest Dermatol, 2012, 132(7):1850-9

PubMed: 22437314 ( click the link to review the publication )
Sci Signal, 2012, 5(224):rs4

PubMed: 22589389 ( click the link to review the publication )

J Neurosci, 2012, 32(1):264-74

PubMed: 22219288 ( click the link to review the publication )

Neoplasia, 2012, 14(1):34-43

PubMed: 22355272 ( click the link to review the publication )

Cancer Sci, 2012, 103(11):1955-60

PubMed: 22925034 ( click the link to review the publication )

J Virol, 2012, 86(8):4578-85

PubMed: 22345463 ( click the link to review the publication )

Mol Pharmacol, 2012, 81(5):748-58

PubMed: 22357666 ( click the link to review the publication )

Hum Pathol, 2012, 43(12):2197-206

PubMed: 22705003 ( click the link to review the publication )

J Surg Oncol, 2012, 106(8):972-80

PubMed: 22711648 ( click the link to review the publication )

PLoS One, 2012, 7(9):e46518

PubMed: 23029544 ( click the link to review the publication )

Blood, 2011, 118(14):3911-21

PubMed: 21821710 ( click the link to review the publication )

Cancer Res, 2011, 71(15):5067-74

PubMed: 21803746 ( click the link to review the publication )

Breast Cancer Res, 2011, 13(3):R52

PubMed: 21595894 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Clin Cancer Res, 2010, 16(24):6029-39

PubMed: 21169255 ( click the link to review the publication )

Cancer Res, 2010, 70(11):4709-18

PubMed: 20484037 ( click the link to review the publication )

Cancer Res, 2010, 70(12):4982-94

PubMed: 20530683 ( click the link to review the publication )

Eur J Cancer, 2010, 46(6):1111-21

PubMed: 20129775 ( click the link to review the publication )

Biochemistry, 2010, 49(39):8488-98

PubMed: 20804212 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description

Targets

p110α ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	mTOR (p70S6K) ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	ATR ^[8] (3T3^TopBP1-ER cells)	View More
4 nM	5 nM	6 nM	7 nM	21 nM	View More

In vitro

BEZ235 significantly reduces the phosphorylation levels of the mTOR activated kinase p70S6K. BEZ235 results in a reduction of S235/S236P-RPS6 levels with IC50 of 6.5 nM. The activity of BEZ235 against mTOR is determined using a biochemical mTOR K-LISA assay with IC50 of 20.7 nM. BEZ235 shows slightly lower activity against its β paralogue with IC50 of 75 nM. The PI3K/Akt/mTOR pathway is often constitutively activated in human tumor cells. BEZ235 blocks PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes. Both PTEN-null cell lines PC3M and U87MG show a dose-dependent reduction in cell proliferation when treated with increasing concentrations of BEZ235 with an average GI50 of 10-12 nM. ^[1] BEZ235 is an mTORC1/2 catalytic inhibitor. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Trypanosoma brucei brucei	NXfiTYNLSW62aX3pZ5Jw[mmjbDDBd5NigQ>?		NWLSZZpJOThiaB?=	M13UVmROW09?	M4rVfGFvfGm2conwZY5we2:vYXygZYN1cX[rdImge4l1cCCHQ{WwJI9nKDBwMECyOUDPxE1?	NITzU3IzPDhyNUm0Oi=>
MCF7	MnrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoHpNE4xOS1zMECg{txO	M3TMZ\|Q5KGh?	NVXoSo5RTE2VTx?=	MUjJR\|UxRTBwN{Og{txO	M{D6SFI{QDdzOUC0
HCT116	MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUnpZWQzOC5yMT2xNFAh\|ryP	NFT0WHI1QCCq	NH3mfZdFVVOR	Mm\YTWM2OD1zLkG2JO69VQ>?	Ml3XNlM5PzF7MES=
U87MG	M1jlbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXm2Z3c3OC5yMT2xNFAh\|ryP	NFjiOXQ1QCCq	NIX4dVlFVVOR	MUfJR\|UxRTFwM{Kg{txO	M{H0T\|I{QDdzOUC0
HBC4	Mn:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;IPXoxNjBzLUGwNEDPxE1?	NYjLdFJZPDhiaB?=		NU\5PIJXVG:pIFfJOVA:NThwNkGgUS=>	NFTM[2YzOjN\|NkK0Oi=>
BSY1	MnPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;xNE4xOS1zMECg{txO	NVjPT5Z7PDhiaB?=		NEjBOlJNd2diR1m1NF0uQC52ODDN	NE\2foUzOjN\|NkK0Oi=>
HBC5	NHX4ZVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF3YN4ExNjBzLUGwNEDPxE1?	MXi0PEBp		MUDMc4chT0l3ME2tO{45PyCP	MWeyNlM{PjJ2Nh?=
MCF7	NXfR[Ik2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvVRZExNjBzLUGwNEDPxE1?	NVS2bHhkPDhiaB?=		M{j5eGxw\yCJSUWwQU05NjF4IF2=	Mn\aNlI{OzZ{NE[=
MDA-MB-231	M{T2SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;ENE4xOS1zMECg{txO	NGTRV2g1QCCq		MX\Mc4chT0l3ME2tPE4xQSCP	MUmyNlM{PjJ2Nh?=
U251	NXmxWIlZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnLoNE4xOS1zMECg{txO	NF\MbpE1QCCq		M2C0T2xw\yCJSUWwQU04NjZ4IF2=	M{P6PFIzOzN4MkS2
SF268	NHv4UI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXye3cxNjBzLUGwNEDPxE1?	NVuzR\|l4PDhiaB?=		Mm\rUI9oKEeLNUC9MVcvQTJiTR?=	M3\q[VIzOzN4MkS2
SF295	MkjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWiwMlAyNTFyMDFOwG0>	NYfhWXNGPDhiaB?=		NHTXOWVNd2diR1m1NF0uQC5\|MTDN	MXSyNlM{PjJ2Nh?=
SF539	NUfMS4lVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\MNnZNOC5yMT2xNFAh\|ryP	MXe0PEBp		Mn[2UI9oKEeLNUC9MVgvPTliTR?=	MWCyNlM{PjJ2Nh?=
SNB75	Mn3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\4VGFZOC5yMT2xNFAh\|ryP	NVrxR5FRPDhiaB?=		NULnN2J2VG:pIFfJOVA:NThwNUigUS=>	MUiyNlM{PjJ2Nh?=
SNB78	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVGwMlAyNTFyMDFOwG0>	NFT0R2o1QCCq		M2ntTGxw\yCJSUWwQU05NjZ3IF2=	M3TiU\|IzOzN4MkS2
HCC2998	M3fjXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fp[FAvODFvMUCwJO69VQ>?	NE\TdmU1QCCq		M3X2[mxw\yCJSUWwQU05NjB3IF2=	NHzGWZIzOjN\|NkK0Oi=>
KM12	MoLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUiwMlAyNTFyMDFOwG0>	MmL6OFghcA>?		MmHQUI9oKEeLNUC9MVcvPTRiTR?=	MXiyNlM{PjJ2Nh?=
HT-29	Mmf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MonsNE4xOS1zMECg{txO	Mo\HOFghcA>?		MX\Mc4chT0l3ME2tO{44PSCP	MYGyNlM{PjJ2Nh?=
HCT15	MoTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\UNE4xOS1zMECg{txO	NILr[5c1QCCq		MkjTUI9oKEeLNUC9MVgvODNiTR?=	NH34TGUzOjN\|NkK0Oi=>
HCT116	NI\1XlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3GyW\|AvODFvMUCwJO69VQ>?	NYXlRopHPDhiaB?=		MkPZUI9oKEeLNUC9MVcvPjFiTR?=	MlLLNlI{OzZ{NE[=
NCI-H23	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXvKXmZPOC5yMT2xNFAh\|ryP	MlvoOFghcA>?		MmX2UI9oKEeLNUC9MVcvPjRiTR?=	NF3EfpczOjN\|NkK0Oi=>
NCI-H226	M3y3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkThNE4xOS1zMECg{txO	MYK0PEBp		MVnMc4chT0l3ME2tPE41PCCP	MX[yNlM{PjJ2Nh?=
NCI-H522	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInrXpgxNjBzLUGwNEDPxE1?	MWC0PEBp		MmW2UI9oKEeLNUC9MVgvPDViTR?=	M1TzclIzOzN4MkS2
NCI-H438	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;XfJl7OC5yMT2xNFAh\|ryP	NXv6elVCPDhiaB?=		NIDs[oRNd2diR1m1NF0uQC5zMTDN	MV2yNlM{PjJ2Nh?=
A549	NUHWN2x3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTNUpZjOC5yMT2xNFAh\|ryP	MX:0PEBp		MWrMc4chT0l3ME2tPE4xPyCP	MVyyNlM{PjJ2Nh?=
DMS273	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2[2clAvODFvMUCwJO69VQ>?	MmnvOFghcA>?		MXvMc4chT0l3ME2tO{45OCCP	NXq4WYxOOjJ\|M{[yOFY>
DMS114	MlrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XC[\|AvODFvMUCwJO69VQ>?	Mmf6OFghcA>?		MULMc4chT0l3ME2tPE4{QSCP	MnLCNlI{OzZ{NE[=
LOXIMVI	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHEcZh[OC5yMT2xNFAh\|ryP	MUe0PEBp		MmnqUI9oKEeLNUC9MVgvPjZiTR?=	M17SVFIzOzN4MkS2
OVCAR3	NUX1T\|U{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjvNE4xOS1zMECg{txO	NHvz[441QCCq		NEjrRYJNd2diR1m1NF0uQC5zNzDN	M1P1d\|IzOzN4MkS2
OVCAR4	MnriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XHeFAvODFvMUCwJO69VQ>?	NW\JS5JEPDhiaB?=		NHfIenFNd2diR1m1NF0uQC53ODDN	NUnFOnhVOjJ\|M{[yOFY>
OVCAR5	NHPVcodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlL4NE4xOS1zMECg{txO	MYe0PEBp		NFnvOIFNd2diR1m1NF0uPy53NzDN	NFrvOmczOjN\|NkK0Oi=>
OVCAR8	NGDwOnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\iNE4xOS1zMECg{txO	M3fHdVQ5KGh?		MYLMc4chT0l3ME2tO{45PCCP	NYG4TVhKOjJ\|M{[yOFY>
SKOV3	NXTndHZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jKSlAvODFvMUCwJO69VQ>?	MnnQOFghcA>?		MYPMc4chT0l3ME2tPE41OSCP	NVX6d\|dqOjJ\|M{[yOFY>
RXF631L	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{Xxb\|AvODFvMUCwJO69VQ>?	MlnrOFghcA>?		MVvMc4chT0l3ME2tPE4zOSCP	NV7sbJN{OjJ\|M{[yOFY>
ACHN	NI\GT5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;QNE4xOS1zMECg{txO	MoTNOFghcA>?		MXvMc4chT0l3ME2tO{46PSCP	MUWyNlM{PjJ2Nh?=
St-4	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HQW\|AvODFvMUCwJO69VQ>?	M1fiNlQ5KGh?		NF\uV4JNd2diR1m1NF0uPy52NzDN	NUjZOHBCOjJ\|M{[yOFY>
MKN1	NFzhVI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYOwMlAyNTFyMDFOwG0>	NFPheGI1QCCq		MYXMc4chT0l3ME2tPE41OSCP	NHv5S24zOjN\|NkK0Oi=>
MKN7	NET2VYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFK1NWcxNjBzLUGwNEDPxE1?	MkD4OFghcA>?		MWHMc4chT0l3ME2tO{43QCCP	MXyyNlM{PjJ2Nh?=
MKN28	MlnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NITQRmkxNjBzLUGwNEDPxE1?	NYrFTplIPDhiaB?=		M2D1SWxw\yCJSUWwQU04NjB5IF2=	MXOyNlM{PjJ2Nh?=
MKN45	NY\t[YlDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHofndEOC5yMT2xNFAh\|ryP	M33wO\|Q5KGh?		Mn\zUI9oKEeLNUC9MVgvOzRiTR?=	MoPoNlI{OzZ{NE[=
MKN74	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVewMlAyNTFyMDFOwG0>	NWiyNoZQPDhiaB?=		M{f6[mxw\yCJSUWwQU04NjR{IF2=	M2DpVlIzOzN4MkS2
DU145	Ml\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYLOcYtDOC5yMT2xNFAh\|ryP	NHHWbGI1QCCq		NEPORZFNd2diR1m1NF0uQC5zNjDN	NXPNRXJkOjJ\|M{[yOFY>
PC3	M3Lr[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlq3NE4xOS1zMECg{txO	NUj4eGpEPDhiaB?=		M4X0e2xw\yCJSUWwQU05NjZ4IF2=	Ml;aNlI{OzZ{NE[=
Trypanosoma brucei brucei	MV3GeY5kfGmxbjDBd5NigQ>?	NUe2bIxOOjByIH7N	NUH6V2xQOTJiaB?=	NX7v[HNZTE2VTx?=	M2nBSGRm[3KnYYPlJIlvKHCqb4PwbI91cWS7bDDpco9{cXSxbDDwbI9{eGijdHWgcIV3\Wx?	NWfOOnVXOjR6MEW5OFY>
Trypanosoma brucei brucei	NVTNdI1bTnWwY4Tpc44hSXO\|YYm=		NUnuNIt5OThiaB?=	NVLmU\|FOTE2VTx?=	MmPzTY5pcWKrdHnvckBw\iC{ZXPldJRwei2vZXTpZZRm\CCnbnTvZ5l1d3OrczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiC2cnHud4ZmenKrbjD1dJRic2V?	NFXXSYozPDhyNUm0Oi=>
Trypanosoma brucei brucei	NHG3R4NHfW6ldHnvckBCe3OjeR?=	M3[5TlIxOCCwTR?=	M{PG[VEzKGh?	NUW2OnJ6TE2VTx?=	NYHWPGF{TW[oZXP0JI9vKHOyaHnu[49ugWynaX6gcIV3\Wx?	M3\h[VI1QDB3OUS2
Trypanosoma brucei brucei	NFSzOoRHfW6ldHnvckBCe3OjeR?=	MUKyNFAhdk1?	NXr1fXFmOTJiaB?=	NEXyXnZFVVOR	NV7oPGlqTW[oZXP0JI9vKHCqb4PwbIF1cWS7bHPoc4xqdmVibHX2[Yw>	MmXaNlQ5ODV7NE[=
UM-UC-3	NI\BeWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2q3UmlEPTB;M{G1JJBO	MX;TRW5ITVJ?
SBC-1	NYTwRY5FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3rmcWlEPTB;N{SyJJBO	NXvGSlFCW0GQR1XS
MKN1	NUnoTJBUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVPZflc2UUN3ME2yMlghdk1?	NV7xeGxGW0GQR1XS
NCI-H720	MoP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mlu4TWM2OD1\|LkW3JI5O	MlHuV2FPT0WU
BFTC-909	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTNwN{Ggcm0>	NGPwV2tUSU6JRWK=
BPH-1	MlXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M33pOmlEPTB;ND63OkBvVQ>?	MUHTRW5ITVJ?
PC-3	NHfwZ3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTVwMEmgcm0>	M2PIUnNCVkeHUh?=
AN3-CA	NYHvO2xET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUWxdFUzUUN3ME21MlU3KG6P	MW\TRW5ITVJ?
HN	Mn[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYrIVVN[UUN3ME21Mlk3KG6P	NHPERmRUSU6JRWK=
HCC2218	MmfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUG4b\|B{UUN3ME22MlYyKG6P	M{W1WnNCVkeHUh?=
KP-4	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlXvTWM2OD15IH7N	MYrTRW5ITVJ?
LU-139	NELHbGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkjXTWM2OD15Lke3JI5O	NUHLd2F3W0GQR1XS
ETK-1	NVfw[XNoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEDhR29KSzVyPUeuPFghdk1?	Mn63V2FPT0WU
Ramos-2G6-4C10	NHHTO49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4S4emlEPTB;OD60PUBvVQ>?	NFr6fVVUSU6JRWK=
MHH-PREB-1	Mn34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4O3bmlEPTB;OT6xNkBvVQ>?	NIPSe\|dUSU6JRWK=
DU-4475	Mni0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFPKeYtKSzVyPUmuOFQhdk1?	MWjTRW5ITVJ?
NCI-H1666	M1jhTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYfJPHp2UUN3ME25MlcyKG6P	MVnTRW5ITVJ?
CAMA-1	M3PrcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3v4VWlEPTB;OT64JI5O	NX\IU3d3W0GQR1XS
TYK-nu	NVrxfGk1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2[wZ2lEPTB;OT65OEBvVQ>?	NH3ONHZUSU6JRWK=
MFE-280	M{\mfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1LoO2lEPTB;OT65PUBvVQ>?	MW\TRW5ITVJ?
A549	NVTTN2hbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTFyLkG0JI5O	NFnYPWtUSU6JRWK=
769-P	NY\IbmExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWXTU\|BlUUN3ME2xNE41PCCwTR?=	M3m5[XNCVkeHUh?=
L-363	NEH0PHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIDWVpdKSzVyPUGwMlY6KG6P	M1PCU3NCVkeHUh?=
ES8	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnuzTWM2OD1zMD65JI5O	Mnq3V2FPT0WU
PA-1	NFTNNnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGGwc4ZKSzVyPUGxMlgzKG6P	MVzTRW5ITVJ?
Mewo	NHPmXGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF;JXWJKSzVyPUGxMlk6KG6P	M2rWO3NCVkeHUh?=
HSC-3	NGXBOJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIfD[3NKSzVyPUGyMlIyKG6P	NF;KbI5USU6JRWK=
H4	M4Hic2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfTNYZKSzVyPUGyMlY4KG6P	NWryU3YxW0GQR1XS
BB65-RCC	M1TBeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2[xTGlEPTB;MUKuO\|Ihdk1?	M1rqTHNCVkeHUh?=
NCI-H1793	M2Ly[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTF{LkiyJI5O	MoHJV2FPT0WU
KARPAS-45	M2m5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLHW25KSzVyPUGzMlUyKG6P	MWPTRW5ITVJ?
GCT	M3PHUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVnVV\|dPUUN3ME2xN{43QCCwTR?=	NInQU4hUSU6JRWK=
EoL-1	M2XSd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTF\|LkmzJI5O	MoPxV2FPT0WU
LB2241-RCC	NHTFcJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1jzT2lEPTB;MUSuNFEhdk1?	Mmf5V2FPT0WU
ES5	MlTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{C2WmlEPTB;MUSuO\|Qhdk1?	NX;RSFl{W0GQR1XS
LOXIMVI	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXpZ2U6UUN3ME2xOE46QSCwTR?=	MXHTRW5ITVJ?
COR-L105	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWWwfZo6UUN3ME2xOU4xPCCwTR?=	MnroV2FPT0WU
P12-ICHIKAWA	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTF3LkGgcm0>	MoHNV2FPT0WU
CHL-1	NWPyOnJUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1vld2lEPTB;MUWuOFUhdk1?	MmTnV2FPT0WU
VMRC-RCZ	Mn3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTF3Lk[zJI5O	MVPTRW5ITVJ?
HH	NUnQXVZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIrDRXFKSzVyPUG1Mlchdk1?	M4myenNCVkeHUh?=
NUGC-3	NITwVWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTF4LkO0JI5O	NGHHVWFUSU6JRWK=
EGI-1	NGD5V49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4TDZ2lEPTB;MU[uOFMhdk1?	NGjVSVBUSU6JRWK=
OS-RC-2	NGHoUHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFz3TZdKSzVyPUG2MlQ4KG6P	M{jHTXNCVkeHUh?=
MOLT-16	NX:5NYhIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY\RfHpRUUN3ME2xO{4yPSCwTR?=	NInjZYxUSU6JRWK=
NCI-H209	M1j4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIrvcYdKSzVyPUG3MlI6KG6P	MX3TRW5ITVJ?
697	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\CZYtKSzVyPUG3MlQ{KG6P	MYXTRW5ITVJ?
D-56MG	M1i3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoGyTWM2OD1zNz62PUBvVQ>?	Mlq5V2FPT0WU
VA-ES-BJ	NIOzcWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH:1dYlKSzVyPUG3Mlg{KG6P	NE\HbohUSU6JRWK=
EW-16	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;qeWRKSzVyPUG4MlA1KG6P	MXTTRW5ITVJ?
HGC-27	MmX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2q2WmlEPTB;MUiuNFYhdk1?	MoLnV2FPT0WU
ES7	MoLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX7zN\|JVUUN3ME2xPE4xQSCwTR?=	NGHvNpFUSU6JRWK=
HuH-7	M3rFWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTF6LkSgcm0>	M3HtVXNCVkeHUh?=
BCPAP	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NILZXppKSzVyPUG4MlY2KG6P	M1nMZXNCVkeHUh?=
SW1710	M4H6emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlrMTWM2OD1zOD63NkBvVQ>?	M3TseHNCVkeHUh?=
IST-MEL1	MnXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkfKTWM2OD1zOD63O{BvVQ>?	NWDNVHM3W0GQR1XS
SF295	M2rXPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVniPVQ{UUN3ME2xPE46OyCwTR?=	NWT4SmtZW0GQR1XS
RPMI-7951	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFn6OIJKSzVyPUG5MlI5KG6P	NYXIcHFKW0GQR1XS
SF126	Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkezTWM2OD1zOT60NUBvVQ>?	NVjjeHN1W0GQR1XS
GAMG	MmCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVfiVIpvUUN3ME2xPU41QCCwTR?=	MlzBV2FPT0WU
KNS-81-FD	M4\5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYjJO2ZRUUN3ME2xPU42PCCwTR?=	M{fCTHNCVkeHUh?=
RT-112	MonMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTF7Lk[2JI5O	M1fqfHNCVkeHUh?=
DEL	M3v5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF7Xc5pKSzVyPUKwMlQ6KG6P	M33rPXNCVkeHUh?=
CGTH-W-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHyyb4JKSzVyPUKwMlY{KG6P	MVzTRW5ITVJ?
HOS	NVft[Wk2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF;CZlRKSzVyPUKxMlA3KG6P	MkmwV2FPT0WU
ES4	NWLiPI0yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYPiRYZzUUN3ME2yNU4xQCCwTR?=	NVG3XlhqW0GQR1XS
RXF393	M1vaUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTJzLkS1JI5O	NEC1XotUSU6JRWK=
NCI-H2030	NYPDUHZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIn5PItKSzVyPUKxMlUzKG6P	M3LGVnNCVkeHUh?=
YH-13	M1rYZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmrBTWM2OD1{MT64PEBvVQ>?	MYHTRW5ITVJ?
HT-1080	M3vBSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmW3TWM2OD1{MT65N{BvVQ>?	NWPoeXNKW0GQR1XS
NCI-SNU-1	Mn;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTJzLkm1JI5O	MWrTRW5ITVJ?
G-402	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXTMcXhmUUN3ME2yNk4yPiCwTR?=	NHPPfYZUSU6JRWK=
786-0	MnzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW\rOVhqUUN3ME2yNk4zQSCwTR?=	M2SzfnNCVkeHUh?=
ME-180	M1e4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTJ{LkSzJI5O	Mn;LV2FPT0WU
NB69	M1PWXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\6[mFKSzVyPUKyMlU{KG6P	NEDxZVNUSU6JRWK=
J-RT3-T3-5	MnrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M132d2lEPTB;MkKuPVYhdk1?	MYrTRW5ITVJ?
TGBC1TKB	MmS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHvoW\|ZKSzVyPUKzMlA2KG6P	NWXLeWVrW0GQR1XS
SW780	M{C0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXP5WmtzUUN3ME2yN{4yOyCwTR?=	NHvF[5lUSU6JRWK=
MG-63	NUXLOG5pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{S4W2lEPTB;MkOuOFUhdk1?	NFnaOFFUSU6JRWK=
BV-173	MlHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vZeWlEPTB;MkOuPFchdk1?	NX64ZVI{W0GQR1XS
CAL-51	M16zb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MknHTWM2OD1{Mz64PUBvVQ>?	MX\TRW5ITVJ?
A375	MnqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkDmTWM2OD1{Mz65N{BvVQ>?	NYKwV3lCW0GQR1XS
MEL-HO	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTJ2LkC0JI5O	NWnwV4J[W0GQR1XS
EFO-27	M4Gwcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NITlVYVKSzVyPUK0MlM{KG6P	MoPjV2FPT0WU
Hs-578-T	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHzBUJBKSzVyPUK0MlU5KG6P	MmLZV2FPT0WU
NBsusSR	NGKwflJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnmVlhiUUN3ME2yOE43KG6P	NG\0dpVUSU6JRWK=
CTB-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7ZTWM2OD1{ND62O{BvVQ>?	MlHnV2FPT0WU
FTC-133	NIG1[lNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV\LOFJSUUN3ME2yOU4yKG6P	NIfHbm5USU6JRWK=
MOLT-4	M1nIdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXTPR5F7UUN3ME2yOU4yOiCwTR?=	M36wfnNCVkeHUh?=
HO-1-N-1	NXfEc25QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWLXbWZIUUN3ME2yOU4yPSCwTR?=	NU\jbJJCW0GQR1XS
ES3	NYf5fmRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUO2XXczUUN3ME2yOU4zOiCwTR?=	M{DDdnNCVkeHUh?=
TI-73	MlWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTJ3LkK4JI5O	MkThV2FPT0WU
MPP-89	M3jOT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4j3cWlEPTB;MkWuN\|Ihdk1?	MnH6V2FPT0WU
KYSE-150	MnnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHzCTnRKSzVyPUK1Mlg6KG6P	MULTRW5ITVJ?
LXF-289	MnX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1PoWmlEPTB;Mk[uNFQhdk1?	MoTNV2FPT0WU
SK-LU-1	NGLsOHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYqwTItXUUN3ME2yOk4yPyCwTR?=	NEPBdJFUSU6JRWK=
HOP-92	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTJ4LkS4JI5O	M4Do[3NCVkeHUh?=
HuO9	M{ftWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1G2VGlEPTB;Mk[uO\|Yhdk1?	M33V[3NCVkeHUh?=
SW962	MkfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTJ4Lke2JI5O	MUDTRW5ITVJ?
RS4-11	NGjIN29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkT5TWM2OD1{Nj65NUBvVQ>?	MlTZV2FPT0WU
NCI-H292	Mlz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3S2PGlEPTB;Mkegcm0>	MX\TRW5ITVJ?
DB	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7tTWM2OD1{Nz6zOkBvVQ>?	M4S1cnNCVkeHUh?=
SW1088	M3X1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M335fmlEPTB;MkiuNlkhdk1?	M{TES3NCVkeHUh?=
A204	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWH6[WIzUUN3ME2yPE41PyCwTR?=	Mme4V2FPT0WU
A3-KAW	NH3Uc\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH;UbXRKSzVyPUK4MlY1KG6P	NUPFXo84W0GQR1XS
MV-4-11	MmW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{LMSWlEPTB;MkiuO{BvVQ>?	NWHwNXlTW0GQR1XS
ES1	M2nRUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{XNPGlEPTB;MkiuPFQhdk1?	NHPU[4tUSU6JRWK=
ONS-76	NWfjUmwzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVXKTW97UUN3ME2yPU4xPSCwTR?=	M3PWd3NCVkeHUh?=
D-263MG	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUj2eVlnUUN3ME2yPU4{PSCwTR?=	NWrKSYl5W0GQR1XS
U-2-OS	MknZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnrVTWM2OD1{OT61JI5O	NVHQPJNNW0GQR1XS
T98G	NVnROXY2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mkn2TWM2OD1{OT64PEBvVQ>?	M{TDOHNCVkeHUh?=
GI-ME-N	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYK1fHljUUN3ME2yPU46OSCwTR?=	NILIXoxUSU6JRWK=
BHT-101	NXfyeFVzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NInYWVZKSzVyPUOwMlA2KG6P	MoDWV2FPT0WU
NOS-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NELLb3BKSzVyPUOwMlEzKG6P	M{nhNnNCVkeHUh?=
AsPC-1	M2m4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3Jbm5KSzVyPUOwMlIhdk1?	M{X2fXNCVkeHUh?=
QIMR-WIL	Mn\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1\QcmlEPTB;M{CuOkBvVQ>?	NXHFWm9pW0GQR1XS
JVM-3	M2nZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWr5UmYxUUN3ME2zNE45OyCwTR?=	MmDHV2FPT0WU
KU-19-19	M2PQ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4rieWlEPTB;M{GuNVMhdk1?	NFvib5VUSU6JRWK=
OVCAR-8	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3nrNmlEPTB;M{GuNlYhdk1?	NHrwPXNUSU6JRWK=
BEN	NGfWOYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXfDSHl1UUN3ME2zNU43OyCwTR?=	NIPDWlBUSU6JRWK=
BE-13	NFi5dXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXjBbIlIUUN3ME2zNU45OiCwTR?=	MkTnV2FPT0WU
EW-18	NVvSSYVqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkjhTWM2OD1\|MT64OkBvVQ>?	MVLTRW5ITVJ?
ECC10	MkP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{nYTGlEPTB;M{GuPVUhdk1?	M2PxPXNCVkeHUh?=
CTV-1	NYXmfGhGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTN{LkiyJI5O	MUPTRW5ITVJ?
COLO-800	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2LwdGlEPTB;M{KuPVIhdk1?	NFn0OIhUSU6JRWK=
A2058	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVu4VVVPUUN3ME2zN{4zPSCwTR?=	M1S0eHNCVkeHUh?=
VM-CUB-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXHTcItwUUN3ME2zN{41OyCwTR?=	MnfpV2FPT0WU
Ca9-22	NETVTW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG[4XWFKSzVyPUOzMlU2KG6P	NWXmVIg2W0GQR1XS
COLO-684	NVrPOGc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUK3[GJWUUN3ME2zN{42QCCwTR?=	NEXWVW9USU6JRWK=
RPMI-8226	NH\UZm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYXBNGt2UUN3ME2zN{45OiCwTR?=	M33odXNCVkeHUh?=
SK-NEP-1	MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Moq5TWM2OD1\|ND6xOUBvVQ>?	NIG0T25USU6JRWK=
Becker	M{X3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWXEfZVqUUN3ME2zOE4zOSCwTR?=	NF7yXoFUSU6JRWK=
NCI-H28	M4PUPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTN2LkS0JI5O	M13ucXNCVkeHUh?=
CAL-120	M121Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoqzTWM2OD1\|ND63NkBvVQ>?	M4fzd3NCVkeHUh?=
MDA-MB-157	MoPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rjPGlEPTB;M{WuOFEhdk1?	NITQXYVUSU6JRWK=
OVCAR-5	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUXMNFlsUUN3ME2zOU41PyCwTR?=	M3LFXHNCVkeHUh?=
LAMA-84	NFTCWmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFu2ZnVKSzVyPUO1Mlg4KG6P	NVS4VXdrW0GQR1XS
CAKI-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2TtT2lEPTB;M{[uOFMhdk1?	M1HCVXNCVkeHUh?=
Daoy	Mln4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3TqT2lEPTB;M{[uO{BvVQ>?	MXjTRW5ITVJ?
CAL-62	NULmb5o3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTN4Lki2JI5O	M2X3XnNCVkeHUh?=
8-MG-BA	M4roS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTN5LkK1JI5O	MV;TRW5ITVJ?
8505C	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\yTWM2OD1\|Nz61NUBvVQ>?	M2DMZ3NCVkeHUh?=
LNCaP-Clone-FGC	M3vYZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEH1O3ZKSzVyPUO3MlU6KG6P	MVjTRW5ITVJ?
CAL-39	NVTJNpdiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzjOHZHUUN3ME2zO{46KG6P	MWDTRW5ITVJ?
MN-60	M4fHZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGT5d5ZKSzVyPUO3Mlk3KG6P	M1W0THNCVkeHUh?=
RKO	NIrST5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTN6LkOzJI5O	MlrOV2FPT0WU
U251	M{D4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWO5N5pLUUN3ME2zPE41OyCwTR?=	M3LMUnNCVkeHUh?=
SJSA-1	NVHTdXpHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3j1S2lEPTB;M{iuOVQhdk1?	NHLZNFVUSU6JRWK=
CAL-12T	NWfU[mV7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHKTWM2OD1\|OD62JI5O	Ml;CV2FPT0WU
HCC1419	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTN6LkexJI5O	NFHQcllUSU6JRWK=
CO-314	M1fzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MofsTWM2OD1\|OD63OEBvVQ>?	NXfwXotbW0GQR1XS
LB1047-RCC	NVWyW2ROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XXU2lEPTB;M{iuPFEhdk1?	M4K2PXNCVkeHUh?=
A101D	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3LlUmlEPTB;M{iuPVchdk1?	M3zWfnNCVkeHUh?=
MDA-MB-175-VII	NF\wV25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2jrbmlEPTB;M{muOVEhdk1?	NXmzPZRzW0GQR1XS
MZ2-MEL	MmfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXvueHZQUUN3ME2zPU43PiCwTR?=	NHPBR2lUSU6JRWK=
NB5	MljiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1H4T2lEPTB;NECuOlQhdk1?	NISwfYFUSU6JRWK=
G-401	M4Pzbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUjJVWJ2UUN3ME20NE45OiCwTR?=	MlfHV2FPT0WU
HT	M2j4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVHqSXc4UUN3ME20NU4xOiCwTR?=	NVnsUVRmW0GQR1XS
8305C	MlPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn\lTWM2OD12MT64O{BvVQ>?	MortV2FPT0WU
BHY	NFrGfFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVP4TmZtUUN3ME20Nk44OiCwTR?=	MkX4V2FPT0WU
NTERA-S-cl-D1	NXrIOJNbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTR\|IH7N	NVPk[4Y5W0GQR1XS
T-24	Ml\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmThTWM2OD12Mz64N{BvVQ>?	M3TEcHNCVkeHUh?=
EPLC-272H	Ml;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWHSRW9KUUN3ME20OE4{QSCwTR?=	NWPqOZdGW0GQR1XS
PSN1	NHLlT5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkjiTWM2OD12ND60JI5O	NULhUoE1W0GQR1XS
NCI-H2452	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUftcXE4UUN3ME20OE42QCCwTR?=	NGHsV4ZUSU6JRWK=
KS-1	Mn\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTR2Lk[2JI5O	MnrhV2FPT0WU
HD-MY-Z	Mn32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlHUTWM2OD12ND65NkBvVQ>?	Ml;VV2FPT0WU
KNS-62	M3XDSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\4OWRuUUN3ME20OU4{QCCwTR?=	MUTTRW5ITVJ?
NOMO-1	M3fRcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1TQZ2lEPTB;NEWuPFchdk1?	MWrTRW5ITVJ?
SK-HEP-1	NInrN4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVy0SplwUUN3ME20Ok4xPCCwTR?=	MnjNV2FPT0WU
IGR-1	M4Ph[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MojSTWM2OD12Nj6xN{BvVQ>?	MoKxV2FPT0WU
KYSE-180	Ml[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlyzTWM2OD12Nj6xO{BvVQ>?	M{mwRnNCVkeHUh?=
EW-22	MlvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mlj4TWM2OD12Nj6yJI5O	MljLV2FPT0WU
NCI-H1355	M{XMU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2Kwd2lEPTB;NE[uN\|Qhdk1?	NUL6[FdHW0GQR1XS
DOHH-2	Mm[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jMSWlEPTB;NE[uN\|chdk1?	MYTTRW5ITVJ?
A4-Fuk	Mn7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml;NTWM2OD12Nj61NkBvVQ>?	NUm4PHI4W0GQR1XS
PC-14	MmDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mmj3TWM2OD12Nj61O{BvVQ>?	NWToRnl1W0GQR1XS
TE-5	NVXsXo02T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mni3TWM2OD12Nj64OEBvVQ>?	NYHnbW1HW0GQR1XS
LB996-RCC	NF7iWWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIH6bnFKSzVyPUS3MlE6KG6P	M2LlfnNCVkeHUh?=
NCI-H1623	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1fwW2lEPTB;NEeuO\|Yhdk1?	M2SySnNCVkeHUh?=
NCI-H1155	MoLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTR6LkOyJI5O	MVHTRW5ITVJ?
LoVo	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVrjZ242UUN3ME20PE41KG6P	NInCS\|hUSU6JRWK=
MCF7	M{X1N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEGydVRKSzVyPUS4MlU5KG6P	Mle5V2FPT0WU
AGS	NEDMWIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7jXZV1UUN3ME20PE44PyCwTR?=	NHvySXNUSU6JRWK=
PFSK-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTR7LkC2JI5O	NFPxWIZUSU6JRWK=
22RV1	NWrGc2xMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLPTWM2OD12OT6wPUBvVQ>?	MX\TRW5ITVJ?
COR-L23	MoL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTR7LkG2JI5O	NVzXRVRGW0GQR1XS
D-283MED	MkjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIT1WXlKSzVyPUS5MlYyKG6P	MoHwV2FPT0WU
SW982	NVXJUHo6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTR7LkmxJI5O	NUXmRowzW0GQR1XS
SW620	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mny0TWM2OD13MD6zOkBvVQ>?	NEPtZZZUSU6JRWK=
KYSE-140	NVLo[WN[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XBTWlEPTB;NUCuOVUhdk1?	NYD2O21NW0GQR1XS
GCIY	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVfLbXBoUUN3ME21NE43PyCwTR?=	MXHTRW5ITVJ?
MHH-ESS-1	NE\NcZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnT4TWM2OD13MT65OUBvVQ>?	NIXPWWRUSU6JRWK=
D-423MG	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2HEUWlEPTB;NUKuNFghdk1?	NHTCW45USU6JRWK=
SF539	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rRZ2lEPTB;NUKuN\|Uhdk1?	M2XFXXNCVkeHUh?=
RPMI-2650	NX3JToVxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlrUTWM2OD13Mj62PUBvVQ>?	NHjXfYJUSU6JRWK=
GR-ST	NYC4PG56T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEnSPWxKSzVyPUWyMlg4KG6P	NY\ienBYW0GQR1XS
YKG-1	M17zTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mk\PTWM2OD13MzDuUS=>	M4TtbXNCVkeHUh?=
SK-MES-1	NETlbmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRTV\|LkK2JI5O	MUXTRW5ITVJ?
HLE	NHO0W2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2jkVWlEPTB;NUOuOFchdk1?	NWHFRpB4W0GQR1XS
RVH-421	Mmf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HRUGlEPTB;NUOuOlchdk1?	MnXqV2FPT0WU
C32	MnfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3PscmlEPTB;NUOuPFMhdk1?	MknaV2FPT0WU
GB-1	MnPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTV2LkKgcm0>	NV3ZVZZNW0GQR1XS
SNB75	MlXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn\WTWM2OD13ND6yOkBvVQ>?	M3XNWXNCVkeHUh?=
EM-2	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHfFXmVKSzVyPUW0MlQhdk1?	NWiwe5pMW0GQR1XS
RH-1	MoPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTV2Lkegcm0>	M{GzRnNCVkeHUh?=
NKM-1	NFe2cYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MofuTWM2OD13ND64NUBvVQ>?	M1fCUnNCVkeHUh?=
NCI-H2405	MnTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTV2Lki4JI5O	M4i2R3NCVkeHUh?=
KYSE-450	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGe4fWJKSzVyPUW1MlE3KG6P	NUXBSoxnW0GQR1XS
A704	Ml3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjRTWM2OD13NT61PUBvVQ>?	NWf4TXlqW0GQR1XS
HAL-01	NF;iRXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTV3LkizJI5O	M4XVe3NCVkeHUh?=
TE-11	NUDQZ\|hsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHe1bnRKSzVyPUW1Mlk6KG6P	MV3TRW5ITVJ?
DOK	M3\QUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIDJcFlKSzVyPUW2MlAzKG6P	MkDlV2FPT0WU
KY821	Mn3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIHrNVVKSzVyPUW2MlIhdk1?	MnTsV2FPT0WU
KGN	NUfn[oNiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEiyVJZKSzVyPUW2MlMzKG6P	NYqwVXI3W0GQR1XS
MC116	NH\YO2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnu2TWM2OD13Nz64JI5O	NEDlOnNUSU6JRWK=
PANC-08-13	M1Pqfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTV6LkCxJI5O	NXPJVFF5W0GQR1XS
KE-37	M3ux[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlPGTWM2OD13OD63O{BvVQ>?	M13QTHNCVkeHUh?=
KYSE-410	NWPE[5NwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUfJR\|UxRTV7LkS3JI5O	MXXTRW5ITVJ?
RO82-W-1	NHHGbmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFrsSYpKSzVyPUW5Mlkhdk1?	MmPGV2FPT0WU
M14	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlr4TWM2OD14MD6wOEBvVQ>?	NEL6[5hUSU6JRWK=
GI-1	MkHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3KSGhKSzVyPU[wMlMhdk1?	M2rLVnNCVkeHUh?=
ML-2	MkHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1TYNmlEPTB;NkCuOlIhdk1?	NICyVYxUSU6JRWK=
BFTC-905	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M123OWlEPTB;NkCuOlUhdk1?	NWSxfmM2W0GQR1XS
DMS-273	MlzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTZyLki3JI5O	MXvTRW5ITVJ?
MDA-MB-361	M3zVT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEXueoJKSzVyPU[xJI5O	NWPGc2JDW0GQR1XS
MSTO-211H	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTZ\|LkWxJI5O	NYLnc3NWW0GQR1XS
MEG-01	MnL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mny3TWM2OD14Mz61NkBvVQ>?	NIC1S\|NUSU6JRWK=
M059J	M1fmRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUDHeZdiUUN3ME22N{42QCCwTR?=	MmXEV2FPT0WU
LN-405	NYrjOGtPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTZ\|Lki1JI5O	MmHGV2FPT0WU
NCI-H1581	NIPkeI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2TlW2lEPTB;NkSuNFMhdk1?	MkjpV2FPT0WU
TCCSUP	NV;PV2FNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXe4XZVzUUN3ME22OE42OyCwTR?=	MYXTRW5ITVJ?
SW872	M2n6eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkfBTWM2OD14ND61O{BvVQ>?	NV7wUJBDW0GQR1XS
KYSE-510	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFHHWJZKSzVyPU[1Mlc2KG6P	NXT0UpJzW0GQR1XS
NCI-H1792	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEX3V4JKSzVyPU[2MlE2KG6P	MXzTRW5ITVJ?
SW13	NHva[VRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\GOYhKSzVyPU[2MlUhdk1?	NGeybWxUSU6JRWK=
TE-8	NG\vcodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2nMcWlEPTB;Nk[uOVIhdk1?	M1nje3NCVkeHUh?=
SCH	Mom2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYi1eHdPUUN3ME22O{4yKG6P	MW\TRW5ITVJ?
NEC8	NHP4dlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVrsRY1GUUN3ME22O{4zPCCwTR?=	NHr2RZFUSU6JRWK=
HuO-3N1	NG\iOGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3rlOGlEPTB;NkeuN\|Ehdk1?	NFXh[2ZUSU6JRWK=
EFM-19	M4jmXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4q5bWlEPTB;NkeuOUBvVQ>?	M1jXN3NCVkeHUh?=
HEC-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlrFTWM2OD14Nz61NkBvVQ>?	MYLTRW5ITVJ?
T47D	M2\nUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX6wWpBJUUN3ME22O{45PyCwTR?=	NFvDfJNUSU6JRWK=
SNU-423	NH7KZ5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\4TWM2OD14Nz65PEBvVQ>?	MVXTRW5ITVJ?
WM-115	M1fFXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVr3SVdjUUN3ME22PE4yPCCwTR?=	NFqwXIVUSU6JRWK=
CaR-1	NY\iUotQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnzjTWM2OD14OD6yOUBvVQ>?	NFzu[opUSU6JRWK=
KU812	NFvafZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{fITGlEPTB;NkiuOlkhdk1?	M2C2PXNCVkeHUh?=
AM-38	NHrq[5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{nZdGlEPTB;NkmuN\|Ehdk1?	M2HROXNCVkeHUh?=
KOSC-2	NH3LPYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkS1TWM2OD14OT65O{BvVQ>?	NVn3VGd4W0GQR1XS
MC-IXC	NWrl[FFbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTdyLkC4JI5O	M2G5OXNCVkeHUh?=
SCC-4	M2jYbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF62RWhKSzVyPUexMlM5KG6P	NW\lPFhzW0GQR1XS
Calu-3	Ml7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXQVGlKSzVyPUexMlk5KG6P	MlrZV2FPT0WU
RPMI-8866	M1XRVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTd{LkiyJI5O	NEfsOGZUSU6JRWK=
OVCAR-4	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTd\|LkO2JI5O	MoLoV2FPT0WU
OAW-42	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH7YR5ZKSzVyPUezMlM6KG6P	M4DteHNCVkeHUh?=
ATN-1	M3jVcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGG4SlNKSzVyPUezMlg4KG6P	MomzV2FPT0WU
CHP-212	M3L5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTd2Lkm1JI5O	MnW4V2FPT0WU
C2BBe1	NGrjWHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PDcGlEPTB;N{WuNFMhdk1?	NWfV[nB7W0GQR1XS
A498	MlPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2DQN2lEPTB;N{WuNVUhdk1?	MVHTRW5ITVJ?
SH-4	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHnPPIdKSzVyPUe1MlIyKG6P	NFO3WHdUSU6JRWK=
SNU-449	M4m1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnnOTWM2OD15NT63PUBvVQ>?	MmfjV2FPT0WU
RD	NFy5OHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrsTWM2OD15NT64OkBvVQ>?	NF;qXVFUSU6JRWK=
PANC-03-27	NYX6VGhIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTd4LkK1JI5O	MoW1V2FPT0WU
S-117	NWfyfGZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;0b2lEPTB;N{[uNlchdk1?	NEn2S2hUSU6JRWK=
SK-MEL-2	NVj4NHl{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MonQTWM2OD15Nj63OUBvVQ>?	MkHSV2FPT0WU
LK-2	NUXLSZFGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTd5LkC1JI5O	M3H1cXNCVkeHUh?=
CP50-MEL-B	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVnEd3VTUUN3ME23O{41KG6P	MU\TRW5ITVJ?
647-V	NUXqc3JVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY\ITokzUUN3ME23PE4xPyCwTR?=	MnfDV2FPT0WU
LU-134-A	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUfUfGQ1UUN3ME23PU4xOyCwTR?=	MlXyV2FPT0WU
5637	NVTRbXJqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUXJR\|UxRTd7LkKzJI5O	M2nwcHNCVkeHUh?=
NCI-H1437	MmfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRThyLkWgcm0>	MmPxV2FPT0WU
NCI-H460	NWjJ[4ZNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUnN[5V6UUN3ME24NU4zOyCwTR?=	NX[xfJNWW0GQR1XS
BxPC-3	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFP2ZnpKSzVyPUixMlQ3KG6P	MULTRW5ITVJ?
CAN	NUPFTppiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYrrTFJNUUN3ME24NU45PCCwTR?=	NXzpd\|hFW0GQR1XS
KINGS-1	NFPKOWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDDTWM2OD16Mj6zNkBvVQ>?	NUXuVnVmW0GQR1XS
OCUB-M	NYW3[FlTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4LvTGlEPTB;OEKuOFEhdk1?	M2fMNHNCVkeHUh?=
KALS-1	Mk\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NILFfG1KSzVyPUiyMlU1KG6P	MlLLV2FPT0WU
OCI-AML2	Mn7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPmXYNDUUN3ME24Nk43OSCwTR?=	MYHTRW5ITVJ?
A253	NXjjfIZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XGTGlEPTB;OEKuOlUhdk1?	Mlv3V2FPT0WU
LCLC-97TM1	MnixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWXrfotWUUN3ME24Nk45PiCwTR?=	M37iWnNCVkeHUh?=
NCI-H520	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M13HdGlEPTB;OEOuNFYhdk1?	M4\EbXNCVkeHUh?=
P30-OHK	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTh\|LkWgcm0>	MkLZV2FPT0WU
SBC-5	NH7sXIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTh\|LkWyJI5O	NIDtRYNUSU6JRWK=
HCE-T	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{nOVGlEPTB;OEOuO\|Qhdk1?	NGfHb2RUSU6JRWK=
JEG-3	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFS2Z5ZKSzVyPUi0MlEhdk1?	MnG1V2FPT0WU
KG-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIHp[FhKSzVyPUi0MlI1KG6P	MkD3V2FPT0WU
MIA-PaCa-2	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\xZnpKSzVyPUi0MlU1KG6P	NFGzV3ZUSU6JRWK=
CAL-33	M4PtU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3TDfGlEPTB;OEWuNFghdk1?	M33WbnNCVkeHUh?=
639-V	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NG\pNZZKSzVyPUi1MlQzKG6P	NGS0ZmJUSU6JRWK=
NCI-H1048	M3izOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnjbVZKSzVyPUi2MlMyKG6P	NHrZSXlUSU6JRWK=
NCI-H1573	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnT2TWM2OD16Nz60PEBvVQ>?	M37iWHNCVkeHUh?=
NCI-H2228	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTh6LkK2JI5O	MV\TRW5ITVJ?
NB14	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTh6LkOgcm0>	NF\ERmxUSU6JRWK=
SCC-25	NXPJcmFsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGjhNXdKSzVyPUi5MlgzKG6P	M1PTPXNCVkeHUh?=
A431	MnfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG\4RlJKSzVyPUi5Mlk4KG6P	NH\F[4hUSU6JRWK=
SN12C	Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTlyLk[yJI5O	Mm\0V2FPT0WU
HuCCT1	NXf5bmFpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3uyR2lEPTB;OUCuO\|Yhdk1?	NHrITGFUSU6JRWK=
LS-123	Ml\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH3XXpdKSzVyPUmyMlE5KG6P	MX7TRW5ITVJ?
CAL-85-1	M4S1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3[0XWlEPTB;OUKuOFghdk1?	NXnKSpdvW0GQR1XS
ES6	MnzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIrrOW5KSzVyPUmyMlg{KG6P	NEnGXnJUSU6JRWK=
NCI-H650	NX;VZm9vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTl2LkC5JI5O	NELHOohUSU6JRWK=
NCI-H446	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHrsNnNKSzVyPUm1MlEzKG6P	M1vHRXNCVkeHUh?=
EW-13	NEnpeI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYG3R5kyUUN3ME25OU44PSCwTR?=	NEjse\|ZUSU6JRWK=
HSC-2	M3r5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkGxTWM2OD17NT64PUBvVQ>?	M2W3WXNCVkeHUh?=
U031	Mkj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXzXPFY3UUN3ME25Ok44OyCwTR?=	NXfZfWRqW0GQR1XS
EW-11	MkPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkL3TWM2OD17Nj64PEBvVQ>?	NUX3SmdHW0GQR1XS
GAK	MoriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVTtSGlZUUN3ME25PE46OyCwTR?=	NGTBW5JUSU6JRWK=
SK-OV-3	NFjQbo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M17NXWlEPTB;MUCwMlA4KG6P	MUXTRW5ITVJ?
OMC-1	M{\EWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1nPc2lEPTB;MUCwMlE5KG6P	M37nVHNCVkeHUh?=
TK10	M3LHPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3j0fGlEPTB;MUCwMlIyKG6P	NHzmW4FUSU6JRWK=
EKVX	NITlemdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH7CVmVKSzVyPUGwNE43KG6P	NXXpVmlWW0GQR1XS
Detroit562	Mly4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\DWFFKSzVyPUGwNk4yPyCwTR?=	M2rISXNCVkeHUh?=
SF268	M{\VVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{DifWlEPTB;MUCyMlM1KG6P	MWjTRW5ITVJ?
SNU-387	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUjzPXN4UUN3ME2xNFQvOTdibl2=	MWHTRW5ITVJ?
MDA-MB-231	M1u1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDrfZVTUUN3ME2xNFUvODZibl2=	MnnmV2FPT0WU
NCI-H1563	NF;wfIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU\Ld2hsUUN3ME2xNFUvOThibl2=	MknTV2FPT0WU
D-502MG	MkXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2W0eWlEPTB;MUC1Mlchdk1?	M1[wZXNCVkeHUh?=
A2780	NGW4XZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX3wRlZuUUN3ME2xNFYvPDdibl2=	MVjTRW5ITVJ?
IA-LM	NF7qO\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTFyNz61NUBvVQ>?	MoDYV2FPT0WU
D-392MG	M3:x[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH33[ZJKSzVyPUGwO{42PCCwTR?=	MVjTRW5ITVJ?
MS-1	NW[wOJJjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVj3W\|dsUUN3ME2xNFcvPzFibl2=	MlzsV2FPT0WU
SW1990	NYjWO\|ZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml60TWM2OD1zMEiuOVQhdk1?	NFTzb3RUSU6JRWK=
HEL	NXHWN2FST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIXJSY5KSzVyPUGwPU4zQSCwTR?=	M4T5ZXNCVkeHUh?=
SW1573	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTFyOT6zNUBvVQ>?	NG\kcphUSU6JRWK=
SW1783	MlrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnzBTWM2OD1zMUCuNlIhdk1?	MoXSV2FPT0WU
COLO-680N	M{\CSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYW2UG12UUN3ME2xNVAvPzZibl2=	M4CwfnNCVkeHUh?=
NCI-N87	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFzCSVlKSzVyPUGxNU4xPCCwTR?=	NWLLWZE{W0GQR1XS
SK-MEL-28	MkexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWHJR\|UxRTFzMT61OUBvVQ>?	M2DxXHNCVkeHUh?=
BT-20	NFzCRoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHnzV\|RKSzVyPUGxNk4xOSCwTR?=	MVLTRW5ITVJ?
NCI-H1648	M3X4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTFzMzDuUS=>	MV3TRW5ITVJ?
no-11	MmjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mlv4TWM2OD1zMUOuNlghdk1?	NIHob2lUSU6JRWK=
MOLT-13	NX3qXWNlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzacZBKSzVyPUGxN{41PCCwTR?=	M2PKeXNCVkeHUh?=
NCI-H2170	NFLzeZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NY\h[XBHUUN3ME2xNVQvPTFibl2=	MoXIV2FPT0WU
HTC-C3	M2XEOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIPLU2tKSzVyPUGxOk45PSCwTR?=	M3zocHNCVkeHUh?=
LU-99A	M3[1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYm0UJNQUUN3ME2xNVcvOjFibl2=	NIXZWZJUSU6JRWK=
HCC2998	MkfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\QUmlEPTB;MUG3MlkzKG6P	M4DRenNCVkeHUh?=
NB13	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLZNndFUUN3ME2xNVcvQTlibl2=	MoLPV2FPT0WU
GT3TKB	NHO0T3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkX3TWM2OD1zMUiuNFghdk1?	M3zndnNCVkeHUh?=
BT-549	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVThSIp5UUN3ME2xNVgvQTVibl2=	MVrTRW5ITVJ?
NCI-H747	M4C0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRTFzOT6zOEBvVQ>?	MX3TRW5ITVJ?
EW-1	M2j4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEX2e2FKSzVyPUGyNE4zKG6P	NHfCZo1USU6JRWK=
LB831-BLC	NVXoTXBMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEDSXnBKSzVyPUGyNE43OyCwTR?=	NWT5WXNNW0GQR1XS
NMC-G1	NVnENnloT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NETRb3RKSzVyPUGyNU4yOSCwTR?=	MYLTRW5ITVJ?
COLO-679	MkjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVz4eXFbUUN3ME2xNlIvOTVibl2=	NFO2S3lUSU6JRWK=
HL-60	M1HRPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYD4[pg5UUN3ME2xNlMvOSCwTR?=	Mm\ZV2FPT0WU
MKN7	NHXQOVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYX4TId{UUN3ME2xNlMvQDNibl2=	NI[3boFUSU6JRWK=
RERF-LC-MS	MnnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWDvfIRFUUN3ME2xNlQvOzFibl2=	NV\q[XBJW0GQR1XS
DMS-114	Mmi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fsPWlEPTB;MUK1MlA6KG6P	NEHSVnNUSU6JRWK=
HuP-T4	MlLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTF{Nj65O{BvVQ>?	M{L4bHNCVkeHUh?=
HCC2157	NF;nSY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTF{Nz61JI5O	MmHUV2FPT0WU
SKG-IIIa	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYjsRmk1UUN3ME2xNlgvQCCwTR?=	MnHtV2FPT0WU
HCT-116	MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;NTWM2OD1zM{CuOlQhdk1?	MknsV2FPT0WU
BB30-HNC	MmHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\LOHdKSzVyPUGzNE44QCCwTR?=	M2PpXnNCVkeHUh?=
KYSE-270	M3nTTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIfQ[lNKSzVyPUGzNE45QCCwTR?=	MUPTRW5ITVJ?
MFM-223	M3ywc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY\NdnBWUUN3ME2xN\|EvPTFibl2=	MVHTRW5ITVJ?
NH-12	MlKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3wZ\|VKSzVyPUGzNk46QSCwTR?=	MULTRW5ITVJ?
U-118-MG	MnHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;5TWM2OD1zM{OuOlIhdk1?	MmXkV2FPT0WU
ESS-1	NIq5WlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRTF\|NT6xPEBvVQ>?	NX\2NYtWW0GQR1XS
D-247MG	NVn4R2N3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTF\|NT6yNUBvVQ>?	MYnTRW5ITVJ?
IGROV-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTF\|NT63OkBvVQ>?	NWj6PWZ3W0GQR1XS
C-33-A	NITXU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF3jXWVKSzVyPUGzOU46PyCwTR?=	NGjDdJNUSU6JRWK=
NCI-H1693	M13qN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1HjZ2lEPTB;MUO2MlEzKG6P	M4DPR3NCVkeHUh?=
MLMA	NGm1T29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEPw[4pKSzVyPUGzOk42QCCwTR?=	NX60R5NvW0GQR1XS
SK-N-AS	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVrGXZk4UUN3ME2xN\|cvOTdibl2=	M{HDc3NCVkeHUh?=
NCI-H1755	NXrjUJVlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH7GOm1KSzVyPUGzPE45PSCwTR?=	NULuZ4JvW0GQR1XS
CHP-134	NXL1Z29CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvibYNKSzVyPUGzPU42PSCwTR?=	MVHTRW5ITVJ?
LS-513	NXz0WGJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1HpVmlEPTB;MUSwMlkyKHCP	NH2wWJBUSU6JRWK=
TE-12	MoLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3XDeGlEPTB;MUSwMlk{KG6P	MVzTRW5ITVJ?
KNS-42	NYKw[49OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3LMe2lEPTB;MUS0MlMhdk1?	MnXMV2FPT0WU
SJRH30	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTF2ND60OEBvVQ>?	MoT0V2FPT0WU
NCI-H1092	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTF2ND61NkBvVQ>?	MV;TRW5ITVJ?
H-EMC-SS	NWD5SXNMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\LTWM2OD1zNE[uPFEhdk1?	MnvVV2FPT0WU
SK-MEL-3	NVXk[44xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3PoO2lEPTB;MUS3MlU2KG6P	MmraV2FPT0WU
SK-N-FI	NYjjcY1wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HVTGlEPTB;MUS3MlU6KG6P	MWHTRW5ITVJ?
NCI-H2126	M{HVTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXjoSYhuUUN3ME2xOFgvOTVibl2=	NYDufVBqW0GQR1XS
NCI-H1299	MlXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\zeoFiUUN3ME2xOVAvOjJibl2=	M1PB[HNCVkeHUh?=
CFPAC-1	NGD5bppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTF3MD62OkBvVQ>?	MWrTRW5ITVJ?
NCI-H661	M3TreGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1PwOWlEPTB;MUWxMlI3KG6P	M1TiWHNCVkeHUh?=
KYSE-70	NHW3RnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFz4XWZKSzVyPUG1NU44QSCwTR?=	NEOzdJFUSU6JRWK=
SW900	NVnQWYd4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\5RWlEPTB;MUW0MlY2KG6P	MljiV2FPT0WU
Ca-Ski	M{\TXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmXDTWM2OD1zNU[uN\|khdk1?	M2\mZXNCVkeHUh?=
HPAF-II	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfSc2tKSzVyPUG1Ok41PyCwTR?=	NYDHcXZNW0GQR1XS
LB2518-MEL	M3faWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1XpSGlEPTB;MUW3MlEhdk1?	MXHTRW5ITVJ?
LC-2-ad	MoDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnZ[lZKSzVyPUG1PE43OiCwTR?=	NH7t[WtUSU6JRWK=
HCC1806	NYS2b4g1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3yc4VKSzVyPUG2O{45QCCwTR?=	NVvTOZM2W0GQR1XS
UACC-62	M1jCOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlW5TWM2OD1zNkiuNFkhdk1?	MXjTRW5ITVJ?
KM-H2	MlXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTF5MD61PEBvVQ>?	MVPTRW5ITVJ?
NCI-H2347	NVPnV\|A1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGX0VYpKSzVyPUG3Nk44OiCwTR?=	MVLTRW5ITVJ?
SCC-15	M1rDVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRTF5Mz62OkBvVQ>?	Mn2xV2FPT0WU
BB49-HNC	M33Ldmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWjtdnlOUUN3ME2xO\|MvQDFibl2=	NHfZbHRUSU6JRWK=
GMS-10	NUDhV4x7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHy1U49KSzVyPUG3N{46PCCwTR?=	NH3l[JBUSU6JRWK=
NCI-H2052	NYXVbXlOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlXrTWM2OD1zN{SuPUBvVQ>?	M{XKOnNCVkeHUh?=
SW626	NX;5TGRmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmf4TWM2OD1zN{[uNFYhdk1?	MnvUV2FPT0WU
MDA-MB-415	MoK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mon0TWM2OD1zN{[uOlEhdk1?	NFXJZ2VUSU6JRWK=
Saos-2	NGXHe2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRTF5OT6zOUBvVQ>?	M3jrT3NCVkeHUh?=
DK-MG	NXTDUJo5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2TjSWlEPTB;MUiwMlMhdk1?	M2Xr[nNCVkeHUh?=
SNU-C2B	MmP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHi3O2dKSzVyPUG4NE44OyCwTR?=	NYXWRXZUW0GQR1XS
A427	MkXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NETrT\|NKSzVyPUG4Nk42PyCwTR?=	MmLEV2FPT0WU
KP-N-YS	MmrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nUSWlEPTB;MUi1JI5O	Mo\4V2FPT0WU
J82	NHnaXGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mli5TWM2OD1zOEWuNVghdk1?	M33oOHNCVkeHUh?=
LS-411N	MnraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTF6Nz6yPEBvVQ>?	NXHzS3hOW0GQR1XS
HCC1937	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;EdlZKSzVyPUG4O{41QSCwTR?=	MoPxV2FPT0WU
OE33	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVP0OYNKUUN3ME2xPFgvQTdibl2=	M4K2R3NCVkeHUh?=
NB7	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUOwR4VYUUN3ME2xPFkvQDlibl2=	Mkm1V2FPT0WU
SW684	NHvUPIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFrsOY5KSzVyPUG5Ok4yOyCwTR?=	NVPENoJnW0GQR1XS
HT-144	NIK2PIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRTF7Nj6xOUBvVQ>?	MoTZV2FPT0WU
SK-MEL-30	M1XWRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmjKTWM2OD1zOU[uNkBvVQ>?	MnzDV2FPT0WU
DBTRG-05MG	M{XkOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4XCbWlEPTB;MUm4MlQ4KG6P	M{C3U3NCVkeHUh?=
NCI-H1395	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoLMTWM2OD1zOUiuPFUhdk1?	NWGxOYVGW0GQR1XS
NCI-H2122	NGDwWnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4PhXmlEPTB;MkCwMlU6KG6P	NGDZU5pUSU6JRWK=
no-10	NYfh[\|k{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfmdVVKSzVyPUKwNU4xPCCwTR?=	M3vjVnNCVkeHUh?=
SW48	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTJyMT6zNUBvVQ>?	NVSwfYp2W0GQR1XS
NCI-H1650	M{niOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M13RfWlEPTB;MkC0MlAyKG6P	NFr5b2dUSU6JRWK=
MZ1-PC	Moe3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\QcY9KSzVyPUKwOU42QCCwTR?=	NFnoOVRUSU6JRWK=
U-266	MmrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVfDWo1XUUN3ME2yNFUvPzlibl2=	M4fHZnNCVkeHUh?=
CAS-1	MonuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTJyNz60OEBvVQ>?	M{Xwb3NCVkeHUh?=
AU565	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDaS4dTUUN3ME2yNVIvQDJibl2=	NInCTJdUSU6JRWK=
UACC-257	M{nvbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV;ROXIzUUN3ME2yNVMvQTlibl2=	NWHtPWdsW0GQR1XS
CAL-27	Mnz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYGzXGZnUUN3ME2yNVcvODVibl2=	NG\UZ5VUSU6JRWK=
NCI-H23	M3HpOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1fNe2lEPTB;MkG5MlM{KG6P	MX;TRW5ITVJ?
TE-6	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV61PZp1UUN3ME2yNVkvPjhibl2=	MmjUV2FPT0WU
TGBC24TKB	NUXpUIZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTJ{Mj6xO{BvVQ>?	NY\Tb4oyW0GQR1XS
TE-1	NXK5XZFQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH7GfGZKSzVyPUKyNk45QCCwTR?=	NF\iSWdUSU6JRWK=
RCC10RGB	NVP5c3dQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTJ{ND6xPUBvVQ>?	MVjTRW5ITVJ?
NCI-H596	NInNblZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLRTWM2OD1{MkiuNlIhdk1?	MnXWV2FPT0WU
SW954	NVXRW\|ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYPI[21TUUN3ME2yN\|MvQDNibl2=	Mn\yV2FPT0WU
NCI-H2087	M1nXZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXHJR\|UxRTJ\|ND61NUBvVQ>?	NUXpdmZQW0GQR1XS
SK-PN-DW	NFT4OmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\KZ5VKSzVyPUKzOU4yQSCwTR?=	NVnSO4NQW0GQR1XS
KM12	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTJ\|NT63JI5O	MmDXV2FPT0WU
BT-474	MmHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTJ\|NT63N{BvVQ>?	MonkV2FPT0WU
IST-MES1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIPY[HNKSzVyPUKzOk42PyCwTR?=	M3exZnNCVkeHUh?=
HT-1197	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4nzUWlEPTB;MkO4MlA6KG6P	MnfXV2FPT0WU
CAL-54	NXLhTpdtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXWS5FTUUN3ME2yN\|gvPDlibl2=	M{GwbnNCVkeHUh?=
NB10	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYLJR\|UxRTJ2MD6wOkBvVQ>?	M4LRSXNCVkeHUh?=
PANC-10-05	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUXMclRmUUN3ME2yOFUvPTZibl2=	NGrI[m5USU6JRWK=
NCI-H522	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWPzXm4{UUN3ME2yOFgvOzFibl2=	NWTDcFZ[W0GQR1XS
A388	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDIOHVrUUN3ME2yOFkvQDJibl2=	NUPIbFZMW0GQR1XS
GOTO	M1f6emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml:3TWM2OD1{NUCuNlkhdk1?	NIXWWYVUSU6JRWK=
KLE	NVviTW16T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX;kcWdlUUN3ME2yOVEvQDdibl2=	NYXISnJ4W0GQR1XS
KYSE-520	NWHJ[JZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnnQTWM2OD1{NUKuPFYhdk1?	NGTIR3NUSU6JRWK=
HCE-4	MnLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXHJR\|UxRTJ4Mj61JI5O	NYTTdYdKW0GQR1XS
KURAMOCHI	MoSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGrqbGdKSzVyPUK2OU46KG6P	M4e2N3NCVkeHUh?=
HCC38	NXr5TnFUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mlf2TWM2OD1{Nk[uOFghdk1?	M2Hnd3NCVkeHUh?=
FADU	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEjjO4RKSzVyPUK2Ok43OyCwTR?=	MlrzV2FPT0WU
CW-2	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmWzTWM2OD1{NkmuPVYhdk1?	NHPGPG1USU6JRWK=
L-428	Mlu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2O0SmlEPTB;Mke1MlE2KG6P	NGTaWWJUSU6JRWK=
HCC1569	M{[0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTJ5NT64OEBvVQ>?	NYXG[5pTW0GQR1XS
NCI-H810	M4PiU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlvVTWM2OD1{N{iuN\|Ehdk1?	NGXuS4hUSU6JRWK=
LB771-HNC	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M37Wb2lEPTB;Mki1Mlg1KG6P	M2jBZnNCVkeHUh?=
LCLC-103H	MkDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUKyd4Z[UUN3ME2yPFUvQTlibl2=	M1HPN3NCVkeHUh?=
EFO-21	Ml\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFXzXoNKSzVyPUK4O{43QCCwTR?=	NI\jS2ZUSU6JRWK=
CAL-72	NGnvS3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DXeGlEPTB;MkmzMlE6KG6P	NVrrW4d{W0GQR1XS
SCC-9	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLkTWM2OD1{OUOuNlIhdk1?	NU[zeo5jW0GQR1XS
COLO-829	MoH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIHPfI9KSzVyPUK5Ok42KG6P	MkDyV2FPT0WU
U-87-MG	MmrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULxSGY1UUN3ME2zNFAvPzNibl2=	NEOyXFRUSU6JRWK=
MZ7-mel	NYj4Rmh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGrVcZhKSzVyPUOyN{44PiCwTR?=	MV\TRW5ITVJ?
NCI-H1770	M32zVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIG0[mFKSzVyPUOyOk44PCCwTR?=	NVfBN2pIW0GQR1XS
ChaGo-K-1	Mnz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGXGNWdKSzVyPUOyPE4yKG6P	NIj1ZXlUSU6JRWK=
SiHa	M1PVOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MW\JR\|UxRTN{OT6yOEBvVQ>?	NIn4V2ZUSU6JRWK=
NCI-SNU-5	MoXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1riOWlEPTB;M{O2Mlc4KG6P	MoDYV2FPT0WU
DJM-1	NUHDO\|JVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3nIO2lEPTB;M{SwMlM{KG6P	NFHMTZdUSU6JRWK=
OE19	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTN2MD61N{BvVQ>?	M2XMS3NCVkeHUh?=
NCI-H1651	Mme0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVrSNVVjUUN3ME2zOFQvOThibl2=	MWXTRW5ITVJ?
COLO-792	NFv5UZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHX2S\|RKSzVyPUO1OE41OiCwTR?=	NWDBd4FZW0GQR1XS
ACHN	MlP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWW3NWdvUUN3ME2zOVYvPzFibl2=	NFTwV4VUSU6JRWK=
TH-3	M2LrUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH7meFNKSzVyPUO3PU46PSCwTR?=	NI\uZWhUSU6JRWK=
HT-1376	NFjCUlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnifoZZUUN3ME2zPFQvQDhibl2=	MWjTRW5ITVJ?
RH-18	NWq2[2ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVXWcZIzUUN3ME2zPVQvPzRibl2=	NH7iZmZUSU6JRWK=
NB6	Moq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkXITWM2OD1\|OU[uOlYhdk1?	M3HwfXNCVkeHUh?=
COLO-320-HSR	NH22UlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHez[3RKSzVyPUSwN{4{PyCwTR?=	M2LBOXNCVkeHUh?=
UACC-893	MnTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljTTWM2OD12ME[uOFchdk1?	MYnTRW5ITVJ?
DSH1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1TL[mlEPTB;NEC2MlkyKG6P	NXjTXGpoW0GQR1XS
TE-10	NH:0V29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\PTWM2OD12MEeuNFEhdk1?	MUTTRW5ITVJ?
HCC70	NXnmR5JOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\jcGlEPTB;NEC5MlIyKG6P	NWnvWXMyW0GQR1XS
TGBC11TKB	M3rwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEPreWtKSzVyPUSxNE4{OyCwTR?=	MV;TRW5ITVJ?
NCI-H727	NEXke41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2LVOWlEPTB;NEGyMlEyKG6P	NVPjW3JbW0GQR1XS
ALL-PO	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1X6bWlEPTB;NEG1MlY6KG6P	NYGzRZBDW0GQR1XS
ABC-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlv5TWM2OD12MkCuOFUhdk1?	MkDNV2FPT0WU
NCI-H69	MoCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\CS3dKSzVyPUSyOk44PiCwTR?=	M3ToPHNCVkeHUh?=
GP5d	NFnHboZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTR\|ND60NUBvVQ>?	NInoeoRUSU6JRWK=
UMC-11	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPmTWM2OD12NUiuN\|Yhdk1?	NFjZPZZUSU6JRWK=
RMG-I	NI[3O5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUjlRo9wUUN3ME20OlcvPTZibl2=	M1\HRnNCVkeHUh?=
YAPC	M3\5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnzHTWM2OD12OUCuOkBvVQ>?	MlPoV2FPT0WU
LS-1034	NUjjfZNtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYXGOpZTUUN3ME20PVEvODZibl2=	MkPyV2FPT0WU
RCM-1	NUXBdmg{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzuNHZKSzVyPUS5Ok43QCCwTR?=	MlLDV2FPT0WU
HCC1954	MoHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYPJR\|UxRTVzMj61JI5O	MX\TRW5ITVJ?
SK-MEL-24	NG\oSHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnzNTWM2OD13MU[uOVEhdk1?	NGTGbXhUSU6JRWK=
NB12	NFfJWnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVLZ[IdHUUN3ME21NlgvPDJibl2=	MmTVV2FPT0WU
SW756	M2fr[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3m4OmlEPTB;NUW0Mlk3KG6P	NYfMRZRTW0GQR1XS
HCC1187	MlnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTV5NT64N{BvVQ>?	MUPTRW5ITVJ?
NCI-H2342	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHXaSWhKSzVyPUW5NE4{QSCwTR?=	NVjkVmZ2W0GQR1XS
NCI-H2291	Mn3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIfMR2NKSzVyPUW5PE4{OSCwTR?=	M3\KZnNCVkeHUh?=
OVCAR-3	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIH0bG9KSzVyPUW5PE46PiCwTR?=	NIPZ[FJUSU6JRWK=
MHH-NB-11	NWfiNZBqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3fl[mlEPTB;NkK5MlAyKG6P	NGjzOopUSU6JRWK=
SAS	NF7QWpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\YTWM2OD14NUKuOlchdk1?	NV7jXYFiW0GQR1XS
COLO-824	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUHxW5p[UUN3ME22PFkvOzdibl2=	NWC2PYNqW0GQR1XS
HCC1395	NIKySIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVHTRmtLUUN3ME22PVgvPSCwTR?=	NVHYXFhlW0GQR1XS
COLO-668	NVH3bWZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHK5[GVKSzVyPUewOk4yKG6P	NETQfIJUSU6JRWK=
NCI-H226	M17YUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2i1S2lEPTB;N{C3Mlghdk1?	NWC3bHhVW0GQR1XS
NB17	MkDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYK2bVNFUUN3ME23NlEvPzVibl2=	MnTKV2FPT0WU
SW1463	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk\VTWM2OD15M{muNVkhdk1?	NHn1THlUSU6JRWK=
TGW	NIXLXmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTd4MD6xOUBvVQ>?	MoLvV2FPT0WU
NCI-H526	M1z5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4j1SWlEPTB;OEKzMlU{KG6P	MkTtV2FPT0WU
COR-L88	NFv6WHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXXvUFRHUUN3ME24OFgvOTJibl2=	MVvTRW5ITVJ?
NCI-H441	M1zJdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVK5TJdTUUN3ME24PVUvOjJibl2=	MWfTRW5ITVJ?
NCI-H630	NWDLVoJUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1eyR2lEPTB;OUGyMlk3KG6P	MXXTRW5ITVJ?
Mo-T	MlTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlnlTWM2OD17NEeuPFghdk1?	NWDWPGdOW0GQR1XS
JAR	MkjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2W1bmlEPTB;OUW2MlI1KG6P	NIKweY1USU6JRWK=
NCI-H1838	M2jreGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NULuPI9FUUN3ME2xMlAzOzh6IN88US=>	NVjMWZB3W0GQR1XS
DoTc2-4510	NVK3SZdXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3S5b2lEPTB;MT6wO\|M4PiEQvF2=	NYnsPWUyW0GQR1XS
MKN28	NV3uc5JzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYrablY2UUN3ME2xMlA6ODJ2IN88US=>	MWLTRW5ITVJ?
HuP-T3	Mmm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M37x[mlEPTB;MT6xNVkxPSEQvF2=	NHTPWoxUSU6JRWK=
TE-9	NIfTe4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVPWSZVzUUN3ME2xMlEzQTd\|IN88US=>	M{nFT3NCVkeHUh?=
NY	NGfwd\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWHsZ2hYUUN3ME2xMlE3Pzl{IN88US=>	M2HHWnNCVkeHUh?=
HT55	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXGWpVKSzVyPUGuN\|E{PDRizszN	M1LDOnNCVkeHUh?=
SW837	M1;Wemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY\u[WZzUUN3ME2xMlMzQTd6IN88US=>	M3OxUnNCVkeHUh?=
NCI-H2029	MojkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk\VTWM2OD1zLkSxO\|kyKM7:TR?=	NXzJcHh{W0GQR1XS
IST-SL1	NX7TdGxUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTFwNESyOEDPxE1?	NUTQbJE2W0GQR1XS
COLO-741	MlLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3fwXWlEPTB;MT60PVc4OSEQvF2=	MlHEV2FPT0WU
LU-65	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnjuTWM2OD1zLk[yNlQ6KM7:TR?=	NWP4N4hXW0GQR1XS
NCI-H1304	MmG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfiWZRKSzVyPUGuOlU1QThizszN	NEPhO2ZUSU6JRWK=
KARPAS-299	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUnDZmdpUUN3ME2xMlc6PDd7IN88US=>	MWTTRW5ITVJ?
NCI-H358	M{n2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmq4TWM2OD1zLkm1OVA{KM7:TR?=	MkfqV2FPT0WU
OAW-28	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3voSGlEPTB;Mj6wOlkyQSEQvF2=	Mli3V2FPT0WU
C8166	NGf4cXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1HKPWlEPTB;Mj62N\|M6OiEQvF2=	NWDyTlJ5W0GQR1XS
COLO-678	NWjuOWZzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{GzZ2lEPTB;Mj64N\|c3QCEQvF2=	NFXPcY9USU6JRWK=
SK-N-DZ	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2HEZ2lEPTB;Mj64OlM5OSEQvF2=	NX7X[HpKW0GQR1XS
NCI-H82	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEHUTI1KSzVyPUKuPVA{PjlizszN	MXPTRW5ITVJ?
JVM-2	NYDDOm1uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIH3O\|RKSzVyPUOuNFMyQDhizszN	Mo\SV2FPT0WU
SW1116	M331NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTNwMEW0NVEh\|ryP	NWj4W2JOW0GQR1XS
MDA-MB-453	NX3jNnZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1TSNmlEPTB;Mz6xNFQ{QSEQvF2=	M12wNnNCVkeHUh?=
Calu-6	MnO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Moq4TWM2OD1\|LkG5PVch\|ryP	MnnNV2FPT0WU
SHP-77	M1XuNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYHNepNGUUN3ME2zMlUzQCEQvF2=	NXnD[Y9RW0GQR1XS
Capan-2	MkizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRTRwM{K1PFEh\|ryP	M3\XbHNCVkeHUh?=
SW948	NVrOU\|RiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU[wXYFjUUN3ME20Mlc1Pzd7IN88US=>	NV;NNXVHW0GQR1XS
HDLM-2	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHq4b2NKSzVyPUWuNFc4OjVizszN	NH62S5JUSU6JRWK=
LAN-6	NHLhdY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{ftU2lEPTB;Nj6yNVQ6PSEQvF2=	NFHOSWVUSU6JRWK=
LU-135	M2H2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn;aTWM2OD14LkSzNFc4KM7:TR?=	MVTTRW5ITVJ?
T84	NWLaS\|FUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTZwOUi2OEDPxE1?	M1\tfnNCVkeHUh?=
CAPAN-1	NWmxemZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVrJVpQxUUN3ME23MlYzOjN\|IN88US=>	MlrUV2FPT0WU
SW1417	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHrTWM2OD15LkmxO\|MyKM7:TR?=	MXnTRW5ITVJ?
BALL-1	MkXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEHieXFKSzVyPUiuOVA1ODlizszN	MWHTRW5ITVJ?
HT-29	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NULsVYF4UUN3ME25MlA4PTl7IN88US=>	MW\TRW5ITVJ?
C3A	NEHVXIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH61cFJKSzVyPUmuPFg{QTRizszN	M2DmbXNCVkeHUh?=
NCI-H1993	M4DJfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NETMNVhKSzVyPUGwMlUxQDFizszN	NH3JXGNUSU6JRWK=
SK-MEL-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTFzLk[yPFkh\|ryP	MmfhV2FPT0WU
DU-145	NYXmVIhOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnfsTWM2OD1zND61NFUzKM7:TR?=	NI\5[2ZUSU6JRWK=
KP-N-YN	NVLoUZVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYDXRXVjUUN3ME2xOE42OTB\|IN88US=>	M{XVPXNCVkeHUh?=
CCRF-CEM	M4jHcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTSTWM2OD1zND63PFA6KM7:TR?=	NGHFWYhUSU6JRWK=
ZR-75-30	M1\Qb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn32TWM2OD1zNj6zN\|A{KM7:TR?=	NIrsfJFUSU6JRWK=
A673	NXHzR3AyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoPwTWM2OD1{MD61OVA4KM7:TR?=	NWexOoptW0GQR1XS
K-562	NXyzS4NiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn3NTWM2OD1{OD60NVg{KM7:TR?=	NFm5VnRUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Myc / Vinculin / pT58 Myc; PubMed: 25934076 Cancer Discov Immunoblots documenting MYC and pT58 MYC stability. SW480 cells were treated with 200nM BEZ235 or solvent control for 24h and cycloheximide (50µg/ml) and harvested at the indicated time points. Vinculin was used as loading control. Exposures of MYC and pT58 MYC blots were adjusted to equalize exposure at 0 min (n=3; unless otherwise indicated, n indicates the number of independent biological repeat experiments in the following legends). pAkt / Akt / Skp2 / AR / pS6 / p27; PubMed: 24347472 Prostate BEZ235 decreases Skp2 and increases AR protein expression inC4-2B cells. Cells were treated with BEZ235 at various doses. Cell lysates were subjected to Westernblot analysis with indicated antibodies. p-S6K / S6K / p-Akt / Akt / p-ABL / BCR-ABL; PubMed: 28435223 Drug Des Devel Ther Dose-dependent inhibition effect of BEZ235 on the phosphorylation levels of S6K, Akt (Ser473), and BCR–ABL in CML cells. Results of Western blot. Bcl-2 / Caspase-3 / Cleaved caspase-3 ; PubMed: 28435223 Drug Des Devel Ther K562 (A1) and KBM7R (A2) cells were treated with BEZ235 for 24 h; total protein lysates were immunoblotted with antibodies for Bcl-2, caspase-3, and cleaved caspase-3. Cyclin D1 / Cyclin D2 ; PubMed: 28435223 Drug Des Devel Ther Dose-dependent inhibition effect of BEZ235 on the expression levels of cyclin D1 and cyclin D2 in K562 and KBM7R cells. Western blot results of K562 (A1) and KBM7R (A2) cells. mTOR / p-mTOR / p70S6K / p-p70S6K ; PubMed: 29581778 J Cancer Eca-109 cells was treated with increasing concentration of BEZ235 (0, 100, 200 and 500 nM) for 48 hours. Western blot showed the inhibition effect of PI3K/mTOR pathway was dose dependent. p-EGFR-Tyr1068 / EGFR / p-HER2-Tyr1221 / p-HER2-Tyr1222 / HER2 / p-HER3-Tyr1289; PubMed: 21278786 Oncogene Immunoblots of protein lysates from BT474 and MCF7-HER2 cells treated with either BEZ235 alone (0–500 n) or the combination of BEZ235 (0–500 n) and the tyrosine kinase inhibitor lapatinib (LAP, 500 n) for 24 h.	25934076 24347472 28435223 29581778 21278786
Immunofluorescence	SP1; PubMed: 26336820 Oncotarget Immunofluorescence assessment of SP1 after BEZ235 treatment for 24 hrs in A673, SKNMC cells and in HFF. p-ErbB2(Y1248); PubMed: 24675532 Cell Res Immunofluorescence staining of BT474.LapR cells grown in 3-D culture under different treatment conditions for a week. Scale bar indicates 50 μm. LC3; PubMed: 23603977 Acta Pharmacol Sin (A) SU-2 cells were treated with NVP-BEZ235 (10 nmol/L) for 12 h and then harvested 24 h after treatment with IR (8 Gy), and analyzed for LC3 expression (top) or the formation of autophagolysosomes by using MDC (middle) and LTR (bottom) by immunofluorescence analysis (600×magnification).	26336820 24675532 23603977
Growth inhibition assay	Cell viability (P3, U87); PubMed: 27542970 BMC Cancer IC50 doses of dactolisib for P3 (left) and U87 (right) glioma cells, generated from MTS assay. Cell viability (breast cancer cells); PubMed: 28060760 Oncotarget Cell viability of breast cancer cells treated by either BEZ235 or TSA for 48h was measured by MTT assay. Each cell line was analyzed in triplicate, and a representative experiment is shown. Cell viability (K562, KBM7R); PubMed: 28435223 Drug Des Devel Ther (A) K562 cells were treated with increasing concentrations of BEZ235 for 24, 48, or 72 h and subjected to MTS assay. (B) KBM7R cells were treated with increasing concentrations of BEZ235 for 24, 48, or 72 h and subjected to MTS assay. (C) K562 cells were treated with imatinib (0–10 μM) alone or imatinib and BEZ235 (0.2 μM) for 48 h and subjected to MTS assay. (D) KBM7R cells were treated with imatinib (0–10 μM) alone or imatinib and BEZ235 (0.2 μM) for 48 h and subjected to MTS assay. Mean ± SD. n=3. *P<0.05, compared to the control group. #P<0.05, compared to the group of IM alone.	27542970 28060760 28435223
ELISA	VEGF; PubMed: 19671762 Mol Cancer Ther NVP-BEZ235 attenuated VEGF secretion by at least 40% in U87 cells. The VEGF level in the serum-free medium was measured in triplicate and the experiment repeated at least twice to confirm results.	19671762

In vivo

BEZ235 induces regression of the tumors (69%) without statistically significant effect on body weight gain. Altogether, these preliminary in vivo efficacy results show that BEZ235 causes disease stasis when administered orally as a single agent and can enhance the efficacy of other anticancer agents when used in combination studies. ^[1]

Protocol

Kinase Assay: ^[1]	- Collapse In vitro Protein Kinase, PI3K, and mTOR Assays: PI3Kα, β, and δ proteins are composed of the iSH2 domain of p85 NH₂-terminally fused to the full-length protein p110 protein, with the exception of α that also does not contain the last 20 amino acids. PI3Kγ is produced as full-length protein deleted for its first 144 amino acids. All constructs are fused to a COOH-terminal His tag for convenient purification and then cloned into the pBlue-Bac4.5 (for α, β, and δ isoforms) or pVL1393 (for γ isoform) plasmids. The different vectors are then cotransfected with BaculoGold WT genomic DNA using methods recommended by the vendor for production of the respective recombinant baculoviruses and proteins. BEZ235 are tested for their activity against PI3K using a Kinase-Glo assay. The kinase reaction is done in 384-well black plate. Each well is loaded with 50 μL of test items (in 90% DMSO) and 5 μL reaction buffer containing 10 μg/mL PI substrate (l-α-phosphatidylinositol; Avanti Polar Lipids; prepared in 3% octyl-glucoside) and the PI3K proteins (10, 25, 10, and 150 nM of p110α, p110β, p110δ, and p110γ, respectively) are then added to it. The reaction is started by the addition of 5 μL of 1 μM ATP prepared in the reaction buffer and is incubated for either 60 (for p110α, p110β, and p110δ) or 120 min (for p110γ). It is terminated by the addition of 10 μL Kinase-Glo buffer. The plates are then read in a Synergy 2 reader for luminescence detection.
Cell Research: ^[2]	- Collapse Cell lines: HCT116, DLD-1 and SW480 cells Concentrations: 0-1 μM Incubation Time: 48 hours Method: The human CRC cell lines, HCT116 (PIK3CA mutant; kinase domain at H1047R), DLD-1 (PIK3CA mutant; helical domain at E545K), and SW480 (PIK3CA wild-type) and isogenic DLD-1 PIK3CA mutant as well as wild-type cells are maintained in DMEM with 10% FBS and 1 × Penicillin/Streptomycin. Cells are plated at different initial densities (HCT116: 3 × 10³ cells/well, DLD-1: 5.5 × 10³ cells/well, SW480: 4.5 × 10³ cells/well, DLD-1 PIK3CA mutant: 7 × 10³ cells/well, and DLD-1 PIK3CA wild-type: 9 × 10³ cells/well) to account for differential growth kinetics. After 16 hours, cells are incubated with increasing concentrations of BEZ235, and the drug-containing growth medium is changed every 24 hours. Cell viability is assessed 16 hours after the initial plating and 48 hours after initiation of drug treatment using the colorimetric MTS assay CellTiter 96® AQueous One Solution Cell Proliferation Assay, as per the manufacturer's instructions. Cell viability after drug treatment is normalized to that of untreated cells also grown for 48 hours. For western blot analysis, cells are plated with zero or maximum inhibitory dose (500 nM) BEZ235 for 2, 6, 24, or 48 hours. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Female Harlan athymic nude mice Formulation: NMP/polyethylene glycol 300 (10/90, v/v) Dosages: 45 mg/kg Administration: p.o. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMF	18 mg/mL warmed (38.33 mM)
	DMSO	0.01 mg/mL (0.02 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): NMP+PEG300 (10+90, v+v) For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dactolisib (BEZ235, NVP-BEZ235) SDF

Molecular Weight	469.55
Formula	C₃₀H₂₃N₅O
CAS No.	915019-65-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01856101	Terminated	Drug: BEZ235	Carcinoma Transitional Cell	Cliniques universitaires Saint-Luc- Université Catholique de Louvain\|Novartis	February 2013	Phase 2
NCT01717898	Terminated	Drug: BEZ235\|Drug: Prednisone\|Drug: Abiraterone acetate	Castrate-resistant Prostate Cancer	Charles Ryan\|Novartis Pharmaceuticals\|University of California San Francisco	January 31 2013	Phase 1\|Phase 2
NCT01756118	Unknown status	Drug: BEZ235	Acute Lymphoblastic Leukemia\|Leukemia Myelocytic Acute\|Chronic Myelogenous Leukemia With Crisis of Blast Cells	Johann Wolfgang Goethe University Hospital	June 2012	Phase 1
NCT01290406	Withdrawn	Drug: BEZ235	Endometrial Cancer	Novartis Pharmaceuticals\|Novartis	March 2012	Phase 2
NCT01288092	Withdrawn	Drug: BEZ235	Metastatic Breast Cancer	Novartis Pharmaceuticals\|Novartis	March 2012	Phase 2
NCT01482156	Completed	Drug: RAD001 + BEZ235	Advanced Solid Tumors\|Metastatic Breast Cancer\|Metastatic Renal Cell Carcinoma	Novartis Pharmaceuticals\|Novartis	January 2012	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
With difficulties in dissolving BEZ235, How can I improve its solubility?
Answer:
For in vivo study, we suggest the vehicle solution NMP/polyethylene glycol 300 (10/90, v/v). Please dissolve BEZ235 in NMP as more as possible. You can sonicate and warm it in water bath for a while. Then dilute with PEG 300.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Selective PI3K Inhibitors

CAL-101 (Idelalisib, GS-1101) : p110δ-selective, IC50=2.5 nM.
Selective PI3K Inhibitors

TGX-221 : p110β-specific, IC50=5 nM.
Most Potent PI3K Inhibitor

Duvelisib (IPI-145, INK1197) : PI3K δ, IC50=1 nM.
FDA-approved PI3K Inhibitor

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
Newest PI3K Inhibitor

GSK2636771 : Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

Related PI3K Products

Taselisib (GDC 0032) ^New

Taselisib (GDC 0032) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

Features:A beta isoform-sparing PI3K inhibitor.
Pilaralisib (XL147) ^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
GNE-317 ^New

GNE-317 is a potent, brain-penetrant PI3K inhibitor.
LY294002

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.
Idelalisib (CAL-101, GS-1101)

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.
Wortmannin

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Buparlisib (BKM120, NVP-BKM120)

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.
Pictilisib (GDC-0941)

Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.
Alpelisib (BYL719)

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Dactolisib (BEZ235, NVP-BEZ235)

Cited by 258 Publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Dactolisib (BEZ235, NVP-BEZ235) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Choose Your Country or Region

By Signaling Pathways

By product type

Dactolisib (BEZ235, NVP-BEZ235)

Cited by 258 Publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Dactolisib (BEZ235, NVP-BEZ235) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)